Metronomic cyclophosphamide regimen selectively dep
and restores T and NK effector functions in end stage ca

Cancer Immunology, Immunotherapy

56, 641-648

DOI: 10.1007/s00262-006-0225-8

Citation Report

#	Article	IF	Citations
1	L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opinion on Biological Therapy, 2007, 7, 1723-1730.	1.4	30
2	T Regulatory Cells Control Numbers of NK Cells and CD8Î±+ Immature Dendritic Cells in the Lymph Node Paracortex. Journal of Immunology, 2007, 179, 4492-4502.	0.4	38
3	Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and Perspectives. Oncology Research and Treatment, 2007, 30, 606-608.	0.8	23
4	Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Molecular Cancer Therapeutics, 2007, 6, 2280-2289.	1.9	47
5	Coadministration of a Herpes Simplex Virus-2â€"Based Oncolytic Virus and Cyclophosphamide Produces a Synergistic Antitumor Effect and Enhances Tumor-Specific Immune Responses. Cancer Research, 2007, 67, 7850-7855.	0.4	50
6	Eradication of Large Tumors in Mice by a Tritherapy Targeting the Innate, Adaptive, and Regulatory Components of the Immune System. Cancer Research, 2007, 67, 8847-8855.	0.4	103
7	Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment. Current Cancer Drug Targets, 2007, 7, 566-581.	0.8	124
8	Chemotherapy Followed by Syngeneic Dendritic Cell Injection in the Mouse: Findings and Implications for Human Treatment. Urology, 2007, 70, S36-S41.	0.5	5
9	Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine, 2007, 25, B89-B96.	1.7	63
10	Therapeutic cancer vaccines. Vaccine, 2007, 25, B1-B3.	1.7	4
11	Interferon-Î³ is produced by another player of innate immune responses: The interferon-producing killer dendritic cell (IKDC). Biochimie, 2007, 89, 872-877.	1.3	24
13	Current Immunotherapeutic Strategies in Colon Cancer. Surgical Oncology Clinics of North America, 2007, 16, 873-900.	0.6	11
15	Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs. Cancer Research and Treatment, 2007, 39, 150.	1.3	42
16	Immunotherapy with dendritic cells for prostate cancer. International Journal of Cancer, 2007, 121, 467-473.	2.3	35
17	Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nature Reviews Cancer, 2007, 7, 880-887.	12.8	379
18	Regulatory T cells and tumour immunity â€" observations in mice and men. Immunology, 2008, 123, 157-163.	2.0	94
19	Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. Clinical and Experimental Immunology, 2007, 150, 523-530.	1.1	104
20	T regulatory cells: aid or hindrance in the clearance of disease?. Journal of Cellular and Molecular Medicine, 2007, 11, 1291-1325.	1.6	14

#	Article	IF	Citations
21	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. Journal of Molecular Medicine, 2007, 85, 1069-1076.	1.7	68
22	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 1513-1537.	2.0	149
23	Prognostic Value of Preoperative Peripheral Blood Monocyte Count in Patients with Colorectal Liver Metastasis after Liver Resection. Journal of Gastrointestinal Surgery, 2007, 11, 596-602.	0.9	51
24	Cancer treatment: the combination of vaccination with other therapies. Cancer Immunology, Immunotherapy, 2008, 57, 1735-1743.	2.0	48
25	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunology, Immunotherapy, 2008, 57, 1579-1587.	2.0	137
26	Immunoregulatory T cells: Role and potential as a target in malignancy. Current Oncology Reports, 2008, 10, 130-136.	1.8	27
27	Targeting tumor vascular endothelium: an emerging concept for cancer therapy. Drug Development Research, 2008, 69, 340-351.	1.4	1
28	Immunogenic anti-cancer chemotherapy as an emerging concept. Current Opinion in Immunology, 2008, 20, 545-557.	2.4	101
29	Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine, 2008, 26, 4716-4724.	1.7	25
30	CD4⁺ Tâ€regulatory cells: toward therapy for human diseases. Immunological Reviews, 2008, 223, 391-421.	2.8	213
31	Natural killer cellâ€“directed therapies: moving from unexpected results to successful strategies. Nature Immunology, 2008, 9, 486-494.	7.0	265
32	DNA vaccines: precision tools for activating effective immunity against cancer. Nature Reviews Cancer, 2008, 8, 108-120.	12.8	388
33	Immunological aspects of cancer chemotherapy. Nature Reviews Immunology, 2008, 8, 59-73.	10.6	1,374
34	Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death and Differentiation, 2008, 15, 13-20.	5.0	57
35	Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clinical Immunology, 2008, 129, 219-229.	1.4	176
36	Dendritic cell-based cancer vaccination:quo vadis?. Expert Review of Vaccines, 2008, 7, 1041-1053.	2.0	20
37	Cancer is not just a disease of a tissue: It is a host disease. Annales D'Endocrinologie, 2008, 69, 151-152.	0.6	2
38	Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends in Molecular Medicine, 2008, 14, 141-151.	3.5	108

#	Article	IF	Citations
39	Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. European Journal of Cancer, 2008, 44, 1875-1882.	1.3	184
41	Development of multi-epitope vaccines targeting wild-typesequence p53 peptides. Expert Review of Vaccines, 2008, 7, 1031-1040.	2.0	33
42	Metronomic Therapy with Cyclophosphamide and Piroxicam Effectively Delays Tumor Recurrence in Dogs with Incompletely Resected Soft Tissue Sarcomas. Journal of Veterinary Internal Medicine, 2008, 22, 1373-1379.	0.6	139
43	Changes in host defence induced by malignancies and antineoplastic treatment: implication for immunotherapeutic strategies. Lancet Oncology, The, 2008, 9, 269-278.	5.1	49
44	Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine. Expert Review of Vaccines, 2008, 7, 995-1003.	2.0	13
45	Coincidential successful treatment of Jessnerâ€“Kanof disease with chemotherapy. Annals of Oncology, 2008, 19, 1360-1361.	0.6	4
46	Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus. Clinical Cancer Research, 2008, 14, 259-269.	3.2	156
47	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. Clinical Cancer Research, 2008, 14, 5242-5249.	3.2	104
48	Combining immunotherapy with classical anticancer therapy. Annals of Oncology, 2008, 19, vii252-vii255.	0.6	1
49	Local Accumulation of FOXP3+ Regulatory T Cells: Evidence for an Immune Evasion Mechanism in Patients with Large Condylomata Acuminata. Journal of Immunology, 2008, 180, 7681-7686.	0.4	43
50	Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells. Clinical Cancer Research, 2008, 14, 2413-2420.	3.2	277
51	A Phase II Study of Thalidomide and Temozolomide in Patients With Brain Metastases From Malignant Melanoma. Lymphopenia Correlates With Response. Ecancermedicalscience, 2008, 2, 91.	0.6	2
52	A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells. Clinical Cancer Research, 2008, 14, 5759-5768.	3.2	111
53	Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas. Clinical Cancer Research, 2008, 14, 5166-5172.	3.2	280
54	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics, 2008, 7, 3670-3684.	1.9	311
55	Overcoming immunosuppressive mechanisms. Annals of Oncology, 2008, 19, vii241-vii247.	0.6	12
56	The anticancer immune response: indispensable for therapeutic success?. Journal of Clinical Investigation, 2008, 118, 1991-2001.	3.9	520
57	Exosomes for the Treatment of Human Malignancies. Hormone and Metabolic Research, 2008, 40, 82-88.	0.7	28

#	Article	IF	Citations
58	T-regulatory cells in tumour-specific vaccination strategies. Expert Opinion on Biological Therapy, 2008, 8, 1365-1379.	1.4	17
60	Immune-Potentiating Effects of the Chemotherapeutic Drug Cyclophosphamide. Critical Reviews in Immunology, 2008, 28, 109-126.	1.0	143
61	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. Journal of Clinical Investigation, 2008, 118, 3751-3761.	3.9	56
62	Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells. Oncology Reports, 2009, , .	1.2	2
63	Metronomic Chemotherapy Against Cancer: From Paradigm to Clinical Practice?. Tumori, 2009, 95, 843-845.	0.6	5
64	Metronomic Chemotherapy: Changing the Paradigm That More Is Better. Current Oncology, 2009, 16, 7-15.	0.9	139
65	Dynamic Interaction between STLV-1 Proviral Load and T-Cell Response during Chronic Infection and after Immunosuppression in Non-Human Primates. PLoS ONE, 2009, 4, e6050.	1.1	10
66	Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Frontiers in Bioscience - Landmark, 2009, Volume, 1761.	3.0	59
67	Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model. Cancer Research, 2009, 69, 4309-4318.	0.4	140
68	T-regulatory cell modulation: the future of cancer immunotherapy?. British Journal of Cancer, 2009, 100, 1697-1703.	2.9	91
69	Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer. Journal of Immunology, 2009, 182, 1746-1755.	0.4	377
70	Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2. Clinical Cancer Research, 2009, 15, 561-569.	3.2	63
71	Enhancing immune responses to tumor-associated antigens. Cancer Biology and Therapy, 2009, 8, 1440-1449.	1.5	56
72	Regulatory T Cells: Major Players in the Tumor Microenvironment. Current Pharmaceutical Design, 2009, 15, 1879-1892.	0.9	68
73	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. Immunotherapy, 2009, 1, 845-853.	1.0	17
74	Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 797-806.	0.6	55
75	Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer. Clinical Cancer Research, 2009, 15, 4954-4962.	3.2	85
76	FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clinical Immunology, 2009, 131, 1-10.	1.4	36

#	Article	IF	Citations
77	Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clinical Immunology, 2009, 133, 333-352.	1.4	37
78	Chemotherapy enhances vaccineâ€induced antitumor immunity in melanoma patients. International Journal of Cancer, 2009, 124, 130-139.	2.3	103
79	Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. International Journal of Cancer, 2009, 125, 1640-1648.	2.3	224
80	Immunization with a P53 synthetic long peptide vaccine induces P53â€specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer, 2009, 125, 2104-2113.	2.3	123
81	Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1239-1244.	1.2	30
82	Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study. Cancer Immunology, Immunotherapy, 2009, 58, 111-120.	2.0	29
83	Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunology, Immunotherapy, 2009, 58, 317-324.	2.0	128
84	Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunology, Immunotherapy, 2009, 58, 615-628.	2.0	100
85	Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunology, Immunotherapy, 2009, 58, 1219-1228.	2.0	127
86	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunology, Immunotherapy, 2009, 58, 1627-1634.	2.0	207
87	Dynamic Behavior and Function of Foxp3+ Regulatory T Cells in Tumor Bearing Host. Cellular and Molecular Immunology, 2009, 6, 3-13.	4.8	68
88	T cellâ€mediated immunoregulation in the gastrointestinal tract. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 505-519.	2.7	66
89	Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens, 2009, 74, 1-10.	1.0	14
90	Clinical Use of Antiâ€CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells. Annals of the New York Academy of Sciences, 2009, 1174, 99-106.	1.8	248
91	Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. Brain Pathology, 2009, 19, 674-693.	2.1	2,884
93	Pharmacologic and Chemical Adjuvants in Tumor Virotherapy. Chemical Reviews, 2009, 109, 3125-3140.	23.0	52
94	Immunotherapy in the landscape of new targeted treatments for nonâ€small cell lung cancer. Molecular Oncology, 2009, 3, 409-424.	2.1	24
95	CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?. Journal of Translational Medicine, 2009, 7, 102.	1.8	88

#	Article	IF	Citations
96	Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. Journal of Translational Medicine, 2009, 7, 18.	1.8	23
98	Metronomic Chemotherapy. Topics in Companion Animal Medicine, 2009, 24, 137-143.	0.4	39
99	Cyclophosphamide Enhances Human Tumor Growth in Nude Rat Xenografted Tumor Models. Neoplasia, 2009, 11, 187-195.	2.3	47
100	Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma. Haematologica, 2009, 94, 16-21.	1.7	16
101	Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects. Current Molecular Medicine, 2009, 9, 673-682.	0.6	26
102	Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases. Current Gene Therapy, 2009, 9, 62-71.	0.9	19
103	Therapeutic Cancer Vaccines. Current Cancer Therapy Reviews, 2010, 6, 163-174.	0.2	1
104	Regulatory T Cells and Skin Tumors. Recent Patents on Inflammation and Allergy Drug Discovery, 2010, 4, 249-254.	3.9	7
105	Chemoimmunotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 295-303.	1.0	91
106	Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC. Journal of Immunotherapy, 2010, 33, 211-218.	1.2	122
107	Regulatory T Cells. Cancer Journal (Sudbury, Mass), 2010, 16, 342-347.	1.0	40
108	Alterations in the Th1/Th2 balance in breast cancer patients using reflexology and scalp massage. Experimental and Therapeutic Medicine, 2010, 1, 97-108.	0.8	21
109	Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunology, Immunotherapy, 2010, 59, 267-277.	2.0	45
110	Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunology, Immunotherapy, 2010, 59, 769-777.	2.0	50
111	Regulatory T Cell as a Target for Cancer Therapy. Archivum Immunologiae Et Therapiae Experimentalis, 2010, 58, 179-190.	1.0	29
112	Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Investigational New Drugs, 2010, 28, 684-689.	1.2	33
113	Antiâ€“CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy. Seminars in Oncology, 2010, 37, 473-484.	0.8	208
114	T regulatory cells, the evolution of targeted immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 7-17.	3.3	25

#	Article	IF	Citations
115	Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cellular Immunology, 2010, 261, 134-143.	1.4	55
116	Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization. Cellular Immunology, 2010, 262, 150-161.	1.4	33
117	The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology, 2010, 116, 222-233.	0.6	33
118	Doseâ€dense temozolomide regimens. Cancer, 2010, 116, 2868-2877.	2.0	89
119	Tumor vaccination for highâ€grade glioma. Pediatric Blood and Cancer, 2010, 55, 1437-1437.	0.8	1
120	Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene, 2010, 29, 1093-1102.	2.6	942
121	Harnessing the immune response to treat cancer. Oncogene, 2010, 29, 6301-6313.	2.6	72
122	Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. British Journal of Cancer, 2010, 103, 52-60.	2.9	74
123	A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. British Journal of Cancer, 2010, 103, 1415-1421.	2.9	60
124	Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Annals of the New York Academy of Sciences, 2010, 1194, 169-178.	1.8	64
125	6.6 Vakzinierung. , 2010, , .		0
126	TGF-ÃŸ signaling, tumor microenvironment and tumor progression: the butterfly effect. Frontiers in Bioscience - Landmark, 2010, 15, 180.	3.0	69
127	Regulatory T Cells. , 2010, , 87-107.		0
128	Immunotoxicology of Pesticides and Chemotherapies. , 2010, , 467-487.		8
129	Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 996-1006.	1.9	102
130	Manipulation of Regulatory T-Cell Function by Immunomodulators: A Boon or a Curse?. Toxicological Sciences, 2010, 117, 253-262.	1.4	13
131	Chemoimmunotherapy Reduces the Progression of Multiple Myeloma in a Mouse Model. Cancer Prevention Research, 2010, 3, 1265-1276.	0.7	28
132	Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?. Clinical and Developmental Immunology, 2010, 2010, 1-9.	3.3	59

#	Article	IF	Citations
133	Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	33
134	A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice. Journal of Immunology, 2010, 185, 5150-5159.	0.4	97
135	Depletion of Regulatory T Cells Facilitates Growth of Established Tumors: A Mechanism Involving the Regulation of Myeloid-Derived Suppressor Cells by Lipoxin A4. Journal of Immunology, 2010, 185, 7199-7206.	0.4	39
136	Unravelling the complexity of cancerâ€“immune system interplay. Expert Review of Anticancer Therapy, 2010, 10, 917-934.	1.1	5
137	Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opinion on Biological Therapy, 2010, 10, 1019-1035.	1.4	80
138	Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology. Current Topics in Microbiology and Immunology, 2010, 344, 61-95.	0.7	32
140	Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors. Clinical Cancer Research, 2010, 16, 3035-3043.	3.2	97
141	Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis. Molecular Therapy, 2010, 18, 1233-1243.	3.7	85
142	Therapeutic Cancer Vaccines in Combination with Conventional Therapy. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	26
143	Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments. Current Medicinal Chemistry, 2010, 17, 3045-3057.	1.2	80
144	Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients. Cancer Biology and Therapy, 2010, 9, 685-693.	1.5	34
145	Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. Molecular Therapy, 2010, 18, 1874-1884.	3.7	201
146	5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cellâ€“Dependent Antitumor Immunity. Cancer Research, 2010, 70, 3052-3061.	0.4	1,098
147	Dendritic Cell-Derived Exosomes for Cancer Immunotherapy: What's Next?. Cancer Research, 2010, 70, 1281-1285.	0.4	278
148	The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention. Neurosurgery Clinics of North America, 2010, 21, 125-137.	0.8	67
149	Interactions Between NK Cells and Regulatory T Cells. , 2010, , 329-343.		1
150	Regulatory T Cells in Cancer. Advances in Cancer Research, 2010, 107, 57-117.	1.9	320
151	A Vaccine Targeting Telomerase Enhances Survival of Dogs Affected by B-cell Lymphoma. Molecular Therapy, 2010, 18, 1559-1567.	3.7	66

#	Article	IF	Citations
152	Metronomic chemotherapy: new rationale for new directions. Nature Reviews Clinical Oncology, 2010, 7, 455-465.	12.5	553
153	Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. Expert Review of Vaccines, 2010, 9, 617-629.	2.0	20
154	Suppressive activity rather than frequency of FoxP3+ regulatory T cells is essential for CA-125â€“specific T-cell activation after abagovomab treatment. Human Immunology, 2010, 71, 36-44.	1.2	7
155	High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44high cells after their selective depletion. Immunobiology, 2010, 215, 182-193.	0.8	8
156	Dendritic-Cell Tumor Vaccines. Transplantation Proceedings, 2010, 42, 3306-3308.	0.3	2
157	Whole tumor antigen vaccines. Seminars in Immunology, 2010, 22, 132-143.	2.7	201
158	Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Seminars in Immunology, 2010, 22, 113-124.	2.7	183
159	Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma. Journal of Veterinary Internal Medicine, 2010, 24, 1118-1123.	0.6	86
160	The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunology, Immunotherapy, 2010, 59, 279-291.	2.0	66
161	Human FOXP3 and cancer. Oncogene, 2010, 29, 4121-4129.	2.6	118
162	From Molecular to Modular Tumor Therapy. , 2010, , .		7
163	Breaking Tolerance in a Mouse Model of Multiple Myeloma by Chemoimmunotherapy. Advances in Cancer Research, 2010, 107, 1-37.	1.9	21
164	Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients. Cancer Research, 2010, 70, 4297-4309.	0.4	197
166	Metronomic Chemotherapy for Metastatic Prostate Cancer. Drugs and Aging, 2010, 27, 689-696.	1.3	21
167	Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy, 2010, 12, 721-734.	0.3	66
168	Selective Depletion of CD4+CD25+Foxp3+ Regulatory T Cells by Low-Dose Cyclophosphamide Is Explained by Reduced Intracellular ATP Levels. Cancer Research, 2010, 70, 4850-4858.	0.4	184
170	Patented cancer vaccines: the promising leads. Expert Opinion on Therapeutic Patents, 2010, 20, 647-660.	2.4	10
171	Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma. Neoplasia, 2011, 13, 187-197.	2.3	30

#	Article	IF	Citations
172	Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. Cancer Research, 2011, 71, 3528-3539.	0.4	72
173	Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses. Molecular Pharmaceutics, 2011, 8, 93-103.	2.3	4
174	High-Grade Gliomas: Dendritic Cell Therapy. , 2011, , 313-333.		0
175	Sarcoma Immunotherapy. Cancers, 2011, 3, 4139-4150.	1.7	3
176	Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?. Future Oncology, 2011, 7, 385-394.	1.1	41
177	Tumors of the Central Nervous System, Volume 2. , 2011, , .		3
178	Cancer immunotherapy comes of age. Nature, 2011, 480, 480-489.	13.7	3,115
179	The microenvironment in follicular lymphoma. Best Practice and Research in Clinical Haematology, 2011, 24, 135-146.	0.7	57
180	Infectious agents in human cancers: Lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV. Cancer Letters, 2011, 305, 263-278.	3.2	50
181	Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. European Journal of Cancer, 2011, 47, 515-519.	1.3	72
182	Cyclophosphamide Potentiates the Antitumor Effect of Immunization with Injection of Immature Dendritic Cells into Irradiated Tumor. Immunological Investigations, 2011, 40, 383-399.	1.0	11
183	Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. International Reviews of Immunology, 2011, 30, 150-182.	1.5	91
184	Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews Clinical Oncology, 2011, 8, 151-160.	12.5	592
185	Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. International Immunopharmacology, 2011, 11, 1802-1808.	1.7	51
186	Clinical potential of phycocyanobilin for induction of T regulatory cells in the management of inflammatory disorders. Medical Hypotheses, 2011, 77, 1031-1033.	0.8	13
187	Lowâ€Dose Cyclophosphamide Selectively Decreases Regulatory T Cells and Inhibits Angiogenesis in Dogs with Soft Tissue Sarcoma. Journal of Veterinary Internal Medicine, 2011, 25, 920-926.	0.6	98
188	How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer and Metastasis Reviews, 2011, 30, 71-82.	2.7	72
189	Recent Advances in Anti-Angiogenic Therapy of Cancer. Oncotarget, 2011, 2, 122-134.	0.8	114

#	Article	IF	Citations
190	Metronomic Chemotherapy for Treatment of Metastatic Disease: From Preclinical Research to Clinical Trials. , 0, , 573-586.		2
191	Control of Advanced Cancer: The Road to Chronicity. International Journal of Environmental Research and Public Health, 2011, 8, 683-697.	1.2	33
192	Carcinoma-Derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-Cell Stimulation. PLoS ONE, 2011, 6, e17922.	1.1	36
193	Immunotherapy for glioma. Current Opinion in Neurology, 2011, 24, 641-647.	1.8	29
194	Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. Journal of Immunotherapy, 2011, 34, 516-523.	1.2	25
195	Nontoxic, Fiscally Responsible, Future of Oncology. Journal of Pediatric Hematology/Oncology, 2011, 33, 1-3.	0.3	26
196	Updated Technology to Produce Highly Immunogenic Dendritic Cell-derived Exosomes of Clinical Grade. Journal of Immunotherapy, 2011, 34, 65-75.	1.2	160
197	Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy. Cancer Journal (Sudbury, Mass), 2011, 17, 351-358.	1.0	75
198	New Perspectives in Glioma Immunotherapy. Current Pharmaceutical Design, 2011, 17, 2439-2467.	0.9	23
199	Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T-Cell Depletion in a Murine Mesothelioma Model. Journal of Thoracic Oncology, 2011, 6, 1578-1586.	0.5	27
200	Dendritic cell generation and CD4+CD25HIGHFOXP3+ Regulatory T cells in human head and neck carcinoma during Radio-chemotherapy. European Journal of Medical Research, 2011, 16, 57.	0.9	21
201	Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer, 2011, 11, 505.	1.1	25
202	Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. Journal of Translational Medicine, 2011, 9, 17.	1.8	32
203	Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes. Clinical Immunology, 2011, 139, 350-359.	1.4	44
204	Targeting Regulatory T Cells in Cancer. Cancer Research, 2011, 71, 6915-6920.	0.4	172
205	Current status and future applications of cellular therapies for cancer. Immunotherapy, 2011, 3, 507-516.	1.0	26
206	Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2011, 125, 65-72.	1.1	115
207	Cancer Immunotherapy and Nanomedicine. Pharmaceutical Research, 2011, 28, 200-214.	1.7	75

#	Article	IF	Citations
208	Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. Cancer Immunology, Immunotherapy, 2011, 60, 133-144.	2.0	29
209	Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunology, Immunotherapy, 2011, 60, 153-160.	2.0	91
210	Exosomes: immune properties and potential clinical implementations. Seminars in Immunopathology, 2011, 33, 419-440.	2.8	450
211	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Seminars in Immunopathology, 2011, 33, 369-383.	2.8	265
212	Contribution of the immune system to the chemotherapeutic response. Seminars in Immunopathology, 2011, 33, 353-367.	2.8	30
213	Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients. Cancer Microenvironment, 2011, 4, 361-375.	3.1	105
214	The ratio of intraâ€tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer. Journal of Surgical Oncology, 2011, 104, 728-733.	0.8	43
215	Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy, 2011, 19, 1737-1746.	3.7	141
216	Vesicular Stomatitis Virus-induced Immune Suppressor Cells Generate Antagonism Between Intratumoral Oncolytic Virus and Cyclophosphamide. Molecular Therapy, 2011, 19, 140-149.	3.7	30
217	The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg). Current Medicinal Chemistry, 2011, 18, 5217-5223.	1.2	68
218	Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease. Cellular and Molecular Immunology, 2011, 8, 289-295.	4.8	8
219	Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies. Current Molecular Medicine, 2011, 11, 365-372.	0.6	64
220	Activating Systemic T-Cell Immunity Against Self Tumor Antigens to Support Oncolytic Virotherapy with Vesicular Stomatitis Virus. Human Gene Therapy, 2011, 22, 1343-1353.	1.4	70
221	Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biology and Therapy, 2011, 12, 112-118.	1.5	37
222	Immunotherapy for Ovarian Cancer: What's Next?. Journal of Clinical Oncology, 2011, 29, 925-933.	0.8	116
223	Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy. Cancer Research, 2011, 71, 5134-5143.	0.4	100
224	Targeting the tumor microenvironment by immunotherapy: part 2. Immunotherapy, 2011, 3, 1385-1408.	1.0	7
225	Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	31

#	Article	IF	Citations
226	Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines. Cancers, 2011, 3, 3114-3142.	1.7	64
227	Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer. International Journal of Breast Cancer, 2011, 2011, 1-6.	0.6	30
228	Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. Clinical Cancer Research, 2011, 17, 841-848.	3.2	70
229	2-Methoxyestradiol Analogue ENMD-1198 Reduces Breast Cancer-Induced Osteolysis and Tumor Burden BothIn VitroandIn Vivo. Molecular Cancer Therapeutics, 2011, 10, 874-882.	1.9	15
230	Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. Journal of Immunology, 2011, 187, 6130-6142.	0.4	59
231	Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. Cancer Research, 2011, 71, 661-665.	0.4	144
232	Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. Cancers, 2011, 3, 2904-2954.	1.7	12
233	Immune Recovery after Cyclophosphamide Treatment in Multiple Myeloma: Implication for Maintenance Immunotherapy. Bone Marrow Research, 2011, 2011, 1-7.	1.7	34
234	Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosineâ€“prostaglandin E2cooperation. Expert Opinion on Biological Therapy, 2011, 11, 1203-1214.	1.4	24
235	Regulatory T Cells in Colorectal Cancer: From Biology to Prognostic Relevance. Cancers, 2011, 3, 1708-1731.	1.7	18
236	The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance. Clinical and Developmental Immunology, 2011, 2011, 1-14.	3.3	75
237	Foxp3+ regulatory T cells and the formation of portal vein tumour thrombus in patients with hepatocellular carcinoma. Canadian Journal of Surgery, 2011, 54, 89-94.	0.5	17
238	Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape. Clinical and Developmental Immunology, 2012, 2012, 1-12.	3.3	39
239	Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. Journal of General Virology, 2012, 93, 2529-2545.	1.3	163
240	Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities. Frontiers in Immunology, 2012, 3, 103.	2.2	5
241	Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis. Molecular Cancer Therapeutics, 2012, 11, 680-689.	1.9	38
242	VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunityâ€“Induced Tumor Regression. Cancer Research, 2012, 72, 1103-1115.	0.4	79
243	Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer. Journal of Immunology, 2012, 189, 5171-5177.	0.4	58

#	Article	IF	Citations
244	Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 852-873.	0.9	76
245	How can chemoimmunotherapy best be used for the treatment of colon cancer?. Immunotherapy, 2012, 4, 1787-1790.	1.0	3
246	Treg infiltration in glioma: a hurdle for antiglioma immunotherapy. Immunotherapy, 2012, 4, 675-678.	1.0	23
247	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. OncoImmunology, 2012, 1, 326-333.	2.1	95
248	Trial watch. OncoImmunology, 2012, 1, 179-188.	2.1	104
249	Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. OncoImmunology, 2012, 1, 1038-1047.	2.1	22
250	Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective. Cancer Research, 2012, 72, 3439-3444.	0.4	205
251	Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects. Clinical and Developmental Immunology, 2012, 2012, 1-12.	3.3	45
252	New Roads Open Up for Implementing Immunotherapy in Mesothelioma. Clinical and Developmental Immunology, 2012, 2012, 1-13.	3.3	21
253	A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas. Clinical Cancer Research, 2012, 18, 1726-1734.	3.2	186
254	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class Iâ€“Modified Peptides. Clinical Cancer Research, 2012, 18, 6485-6496.	3.2	61
255	Improvement of Antitumor Effect of Intratumoral Injection of Immature Dendritic Cells Into Irradiated Tumor by Cyclophosphamide in Mouse Colon Cancer Model. Journal of Immunotherapy, 2012, 35, 607-614.	1.2	20
256	Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy. Current Pharmaceutical Biotechnology, 2012, 13, 1817-1833.	0.9	59
257	Vaccines for Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2012, 18, 642-652.	1.0	35
258	Dendritic cell-based immunotherapy in mesothelioma. Immunotherapy, 2012, 4, 1011-1022.	1.0	10
259	Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunology, Immunotherapy, 2012, 61, 1791-1804.	2.0	103
260	Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. Cancer Research, 2012, 72, 1621-1631.	0.4	117
261	Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Research and Treatment, 2012, 135, 459-467.	1.1	48

#	Article	IF	Citations
262	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncology, The, 2012, 13, e32-e42.	5.1	219
263	Immune Tolerance to Tumor Antigens Occurs in a Specialized Environment of the Spleen. Cell Reports, 2012, 2, 628-639.	2.9	196
264	T cell subsets and colorectal cancer: Discerning the good from the bad. Cellular Immunology, 2012, 279, 21-24.	1.4	17
265	Immunotherapy for metastatic colorectal cancer: Present status and new options. Scandinavian Journal of Gastroenterology, 2012, 47, 315-324.	0.6	22
266	Induced and natural regulatory T cells in human cancer. Expert Opinion on Biological Therapy, 2012, 12, 1383-1397.	1.4	105
267	The secret ally: immunostimulation by anticancer drugs. Nature Reviews Drug Discovery, 2012, 11, 215-233.	21.5	591
268	Cyclophosphamide inhibits the generation and function of CD8+ regulatory T cells. Human Immunology, 2012, 73, 207-213.	1.2	27
269	Immunotherapy: A useful strategy to help combat multidrug resistance. Drug Resistance Updates, 2012, 15, 106-113.	6.5	42
270	Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. European Journal of Cancer, 2012, 48, 1774-1780.	1.3	67
271	Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma â€“ A report from the SociÃ©tÃ© FranÃ§aise des Cancers et leucÃ©mies de lâ€™Enfant et de lâ€™adolescent (SFCE). European Journal of Cancer, 2012, 48, 2409-2416.	1.3	57
272	Substantially Modified Ratios of Effector to Regulatory T Cells During Chemotherapy in Ovarian Cancer Patients Return to Pre-Treatment Levels at Completion: Implications for Immunotherapy. Cancers, 2012, 4, 581-600.	1.7	12
273	Immunosuppressive drugs on inducing Ag-specific CD4+CD25+Foxp3+ Treg cells during immune response in vivo. Transplant Immunology, 2012, 27, 30-38.	0.6	43
274	Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Molecular Oncology, 2012, 6, 1-14.	2.1	48
275	Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. Medical Oncology, 2012, 29, 3626-3633.	1.2	17
276	Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. British Journal of Cancer, 2012, 107, 1107-1115.	2.9	54
279	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, 2012, 18, 1254-1261.	15.2	721
280	Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. Hepatology, 2012, 56, 474-483.	3.6	23
281	Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. International Journal of Cancer, 2012, 131, 641-651.	2.3	34

#	Article	IF	Citations
282	Potentiation of a p53â€SLP vaccine by cyclophosphamide in ovarian cancer: A singleâ€arm phase II study. International Journal of Cancer, 2012, 131, E670-80.	2.3	81
283	Targeting regulatory T cells. Targeted Oncology, 2012, 7, 15-28.	1.7	67
284	Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy, 2012, 61, 629-641.	2.0	109
285	Dynamics of Antitumor Resistance after Cyclophosphamide Injection. Bulletin of Experimental Biology and Medicine, 2012, 152, 613-614.	0.3	2
286	Lowâ€dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGFâ€Aâ€mediated angiogenesis. Apmis, 2012, 120, 147-156.	0.9	12
287	Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?. Critical Reviews in Oncology/Hematology, 2012, 82, 40-50.	2.0	114
288	The Potential Beneficial Effects of Drugs on the Immune Response to Vaccination. Seminars in Oncology, 2012, 39, 340-347.	0.8	10
289	Tregs in infection and vaccinology: heroes or traitors?. Microbial Biotechnology, 2012, 5, 260-269.	2.0	45
290	Regulatory T cell: a protection for tumour cells. Journal of Cellular and Molecular Medicine, 2012, 16, 425-436.	1.6	57
291	What are regulatory T cells (Treg) regulating in cancer and why?. Seminars in Cancer Biology, 2012, 22, 327-334.	4.3	242
292	Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunology, Immunotherapy, 2012, 61, 353-362.	2.0	196
293	Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2012, 138, 333-339.	1.2	18
294	Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. Gene Therapy, 2013, 20, 262-273.	2.3	31
295	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine, 2013, 11, 149.	1.8	57
296	Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. Journal of Translational Medicine, 2013, 11, 147.	1.8	56
297	Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients. Journal of Translational Medicine, 2013, 11, 135.	1.8	57
298	Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunology, Immunotherapy, 2013, 62, 405-410.	2.0	81
299	Safety and Efficacy of a Genetic Vaccine Targeting Telomerase Plus Chemotherapy for the Therapy of Canine B-Cell Lymphoma. Human Gene Therapy, 2013, 24, 728-738.	1.4	47

#	Article	IF	Citations
300	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer, 2013, 13, 190.	1.1	11
301	Genetic Vaccines against Cancer. , 2013, , 223-239.		1
302	Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. International Journal of Hematology, 2013, 97, 92-97.	0.7	7
303	Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. Clinical and Experimental Metastasis, 2013, 30, 1047-1062.	1.7	52
305	Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. Cancer Immunology, Immunotherapy, 2013, 62, 1463-1474.	2.0	42
306	Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunology, Immunotherapy, 2013, 62, 1053-1060.	2.0	42
307	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunology, Immunotherapy, 2013, 62, 897-908.	2.0	31
308	Exploiting dendritic cells in the development of cancer vaccines. Expert Review of Vaccines, 2013, 12, 1195-1210.	2.0	15
309	A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British Journal of Cancer, 2013, 109, 1725-1734.	2.9	38
310	Clinical significance of Treg cell frequency in acute myeloid leukemia. International Journal of Hematology, 2013, 98, 558-562.	0.7	37
311	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research, 2013, 19, 4801-4815.	3.2	178
312	CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clinical Cancer Research, 2013, 19, 5300-5309.	3.2	596
313	The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities. Immunologic Research, 2013, 57, 52-69.	1.3	37
314	Cancer Immunotherapy. Surgical Oncology Clinics of North America, 2013, 22, 765-783.	0.6	27
315	Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. Immunity, 2013, 39, 74-88.	6.6	739
316	Clinical opportunities and challenges in targeting tumour dormancy. Nature Reviews Clinical Oncology, 2013, 10, 41-51.	12.5	59
317	Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer. Nature Reviews Drug Discovery, 2013, 12, 51-63.	21.5	181
318	FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunology, Immunotherapy, 2013, 62, 17-25.	2.0	12

#	Article	IF	Citations
319	Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunology, Immunotherapy, 2013, 62, 171-182.	2.0	63
320	Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunology, Immunotherapy, 2013, 62, 203-216.	2.0	215
321	Impact of chemotherapeutic agents on the immunostimulatory properties of human 6â€sulfo LacNAc⁺ (slan) dendritic cells. International Journal of Cancer, 2013, 132, 1351-1359.	2.3	17
322	Immunochemoradiotherapy for Patients with Oral Squamous Cell Carcinoma: Augmentation of OK-432-Induced Helper T Cell 1 Response by 5-FU and X-ray Irradiation. Neoplasia, 2013, 15, 805-814.	2.3	18
323	Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma. Translational Oncology, 2013, 6, 511-519.	1.7	42
324	Challenges in cancer vaccine development for hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 897-903.	1.8	87
325	CD8+ Tumor-Infiltrating T Cells Are Trapped in the Tumor-Dendritic Cell Network. Neoplasia, 2013, 15, 85-IN26.	2.3	84
326	Chemotherapy in the management of advanced cutaneous malignant melanoma. Clinics in Dermatology, 2013, 31, 290-297.	0.8	80
327	Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clinical and Experimental Immunology, 2012, 171, 36-45.	1.1	188
328	T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. Journal of Translational Medicine, 2013, 11, 5.	1.8	27
329	Molecular/Targeted Therapy of Cancer. , 2013, , 215-244.		0
330	Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncology, 2013, 9, 451-462.	1.1	43
331	Inducers of immunogenic cancer cell death. Cytokine and Growth Factor Reviews, 2013, 24, 319-333.	3.2	209
332	Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cellular and Molecular Immunology, 2013, 10, 222-229.	4.8	139
333	A Review of Dendritic Cell Therapy for Cancer: Progress and Challenges. BioDrugs, 2013, 27, 453-468.	2.2	27
334	HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. Molecular Diagnosis and Therapy, 2013, 17, 85-99.	1.6	163
335	Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients. Molecular Therapy, 2013, 21, 1212-1223.	3.7	146
336	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemotherapy and Pharmacology, 2013, 72, 13-33.	1.1	81

#	Article	IF	Citations
337	Therapeutic vaccines for ovarian cancer. Gynecologic Oncology, 2013, 130, 667-673.	0.6	16
338	Cancer Immunotherapy. , 2013, , 198-214.		2
340	The Tumor Immunoenvironment. , 2013, , .		4
341	Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunology, Immunotherapy, 2013, 62, 383-391.	2.0	100
342	A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. European Journal of Cancer, 2013, 49, 35-44.	1.3	41
343	Safety and efficacy of a genetic vaccine targeting Telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. , 2013, 1, P212.		0
344	Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. International Journal of Cancer, 2013, 132, 2471-2478.	2.3	100
345	Phase I clinical trial combining imatinib mesylate and IL-2. OncoImmunology, 2013, 2, e23080.	2.1	29
346	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Review of Vaccines, 2013, 12, 597-615.	2.0	60
347	Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. Future Oncology, 2013, 9, 1375-1388.	1.1	15
348	Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. Frontiers in Immunology, 2013, 4, 197.	2.2	70
349	Metronomic therapy: Chemotherapy revisited. Indian Journal of Cancer, 2013, 50, 142.	0.2	18
350	Natural and Induced T Regulatory Cells in Cancer. Frontiers in Immunology, 2013, 4, 190.	2.2	202
351	Triptolide Downregulates Treg Cells and the Level of IL-10, TGF-Î², and VEGF in Melanoma-Bearing Mice. Planta Medica, 2013, 79, 1401-1407.	0.7	37
352	Adenosine and Prostaglandin E2 Production by Human Inducible Regulatory T Cells in Health and Disease. Frontiers in Immunology, 2013, 4, 212.	2.2	53
353	Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 432-442.	1.3	19
354	Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology, 2013, 2, e22664.	2.1	154
355	Immune effects of 5-fluorouracil. OncoImmunology, 2013, 2, e23139.	2.1	35

#	Article	IF	Citations
356	Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy. Journal of Immunotherapy, 2013, 36, 477-489.	1.2	299
357	Immunotherapeutics for breast cancer. Current Opinion in Oncology, 2013, 25, 602-608.	1.1	27
358	Cancer vaccines. OncoImmunology, 2013, 2, e23403.	2.1	62
359	Phase II Trial of a GM-CSF-producing and CD40L-expressing Bystander Cell Line Combined With an Allogeneic Tumor Cellâ€"based Vaccine for Refractory Lung Adenocarcinoma. Journal of Immunotherapy, 2013, 36, 442-450.	1.2	31
360	Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer. Human Gene Therapy Clinical Development, 2013, 24, 134-142.	3.2	112
361	Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. Journal of Experimental Medicine, 2013, 210, 1153-1165.	4.2	120
362	Maintenance Chemotherapy for Advanced Nonâ€"Small-Cell Lung Cancer: New Life for an Old Idea. Journal of Clinical Oncology, 2013, 31, 1009-1020.	0.8	125
363	Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSFâ€"Coding Oncolytic Adenovirus. Clinical Cancer Research, 2013, 19, 2734-2744.	3.2	150
364	Combining low-dose or metronomic chemotherapy with anticancer vaccines. OncoImmunology, 2013, 2, e27058.	2.1	30
365	Lowâ€dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. International Journal of Cancer, 2013, 133, 98-107.	2.3	138
366	Cytosine Arabinoside Promotes Cytotoxic Effect of T Cells on Leukemia Cells Mediated by Bispecific Antibody. Human Gene Therapy, 2013, 24, 751-760.	1.4	8
367	Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. International Journal of Cancer, 2013, 133, 1479-1488.	2.3	23
368	Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. Annals of Oncology, 2013, 24, 2310-2316.	0.6	25
369	Escalating Regulation of 5T4-Specific IFN-Î³+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy. Cancer Immunology Research, 2013, 1, 416-425.	1.6	15
370	Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation. Molecular and Clinical Oncology, 2013, 1, 649-654.	0.4	26
371	Combined use of cyclophosphamide and Chalone 19-peptide in experimental breast cancer. OncoTargets and Therapy, 2013, 6, 861.	1.0	4
372	Update on the challenges and recent advances in cancer immunotherapy. ImmunoTargets and Therapy, 2013, 2, 39.	2.7	8
373	Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells. PLoS ONE, 2013, 8, e65181.	1.1	103

#	Article	IF	Citations
374	Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer â€“ A Substudy of the Neoadjuvant GeparQuinto Trial. PLoS ONE, 2013, 8, e79775.	1.1	187
375	Dendritic Cell Vaccination in Pediatric Gliomas: Lessons Learnt and Future Perspectives. Frontiers in Pediatrics, 2013, 1, 12.	0.9	9
376	New Insights into the Role of the Immune Microenvironment in Breast Carcinoma. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	50
377	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. ImmunoTargets and Therapy, 2014, 3, 151.	2.7	12
378	Combined Treatment of Murine Fibrosarcoma with Chemotherapy (Paclitaxel), Radiotherapy, and Intratumoral Injection of Dendritic Cells. Annals of Dermatology, 2014, 26, 53.	0.3	7
379	Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art. Critical Reviews in Immunology, 2014, 34, 399-432.	1.0	13
380	IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 3179-3189.	1.4	44
381	Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death and Differentiation, 2014, 21, 15-25.	5.0	740
382	Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy, 2014, 6, 1279-1293.	1.0	34
383	Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology. Immunologic Research, 2014, 60, 156-164.	1.3	3
384	Immunotherapy of HPV infection-caused genital warts using low dose cyclophosphamide. Expert Review of Clinical Immunology, 2014, 10, 791-799.	1.3	5
385	Immunotherapy for Lung Cancer: Has it Finally Arrived?. Frontiers in Oncology, 2014, 4, 288.	1.3	32
386	Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch. Frontiers in Oncology, 2014, 4, 76.	1.3	31
387	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Frontiers in Immunology, 2014, 5, 122.	2.2	75
388	Bilateral Jessner lymphocytic infiltration in the ear lobes: A case report and Literature review. Journal of Clinical and Experimental Investigations, 2014, 5, .	0.1	0
389	Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Frontiers in Oncology, 2014, 4, 145.	1.3	54
390	Dendritic cell vaccination for glioblastoma multiforme: Clinical experience and future directions. , 2014, , .		0
391	Metronomic Chemotherapy. , 2014, , .		3

#	Article	IF	Citations
392	Monitoring the Frequency and Function of Regulatory T Cells and Summary of the Approaches Currently Used to Inhibit Regulatory T Cells in Cancer Patients. Methods in Molecular Biology, 2014, 1139, 201-221.	0.4	3
393	Advances in Tumor Immunology and Immunotherapy. , 2014, , .		2
394	Immune regulation of bone metastasis. BoneKEy Reports, 2014, 3, 600.	2.7	28
395	(R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment. Journal of the National Cancer Institute, 2014, 107, dju347-dju347.	3.0	4
396	IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncology, 2014, 10, 937-948.	1.1	10
397	The â€œTrojan Horseâ€•Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment. Journal of Immunology Research, 2014, 2014, 1-14.	0.9	37
398	Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. OncoImmunology, 2014, 3, e953407.	2.1	32
399	Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation. Acta Haematologica, 2014, 132, 226-232.	0.7	6
400	Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells. Immunological Investigations, 2014, 43, 517-534.	1.0	10
401	Adoptive immunotherapy of metastatic breast cancer: present and future. Cancer and Metastasis Reviews, 2014, 33, 309-320.	2.7	18
402	Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer. Cancer Research, 2014, 74, 104-118.	0.4	319
403	Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells. Cancer Research, 2014, 74, 2663-2668.	0.4	123
404	Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death and Differentiation, 2014, 21, 79-91.	5.0	395
406	Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Reviews, 2014, 28, 249-261.	2.8	16
407	Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation. Cancer Immunology Research, 2014, 2, 616-631.	1.6	408
408	Antibody-based immunotherapy for ovarian cancer: where are we at?. Annals of Oncology, 2014, 25, 322-331.	0.6	38
409	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	0.6	164
410	Metronomic Chemotherapy in Veterinary Patients with Cancer. Veterinary Clinics of North America - Small Animal Practice, 2014, 44, 817-829.	0.5	26

#	Article	IF	Citations
411	Management of Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , .	0.0	2
412	Harnessing the Intestinal Microbiome for Optimal Therapeutic Immunomodulation. Cancer Research, 2014, 74, 4217-4221.	0.4	39
413	A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis. Journal of the National Cancer Institute, 2014, 106, 1-13.	3.0	649
414	Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Molecular Cancer, 2014, 13, 158.	7.9	24
415	Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. Journal of Translational Medicine, 2014, 12, 245.	1.8	12
416	A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials. Biomarkers in Medicine, 2014, 8, 893-911.	0.6	18
417	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. International Journal of Cancer, 2014, 135, 2834-2846.	2.3	31
418	New insights into metronomic chemotherapy-induced immunoregulation. Cancer Letters, 2014, 354, 220-226.	3.2	46
419	Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/Hâ€2K^dâ€specific CD8⁺ T cells. International Journal of Cancer, 2014, 134, 2841-2852.	2.3	9
420	Therapeutic vaccines for cancer: an overview of clinical trials. Nature Reviews Clinical Oncology, 2014, 11, 509-524.	12.5	636
421	The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia, 2014, 28, 1784-1792.	3.3	77
423	Prognostic value of FOXP3 and TGF-Î² expression in both peripheral blood and lymph nodes in patients with B-Non Hodgkinâ€™s lymphoma. Alexandria Journal of Medicine, 2014, 50, 253-265.	0.4	2
424	Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression. Neoplasia, 2014, 16, 84-W27.	2.3	65
425	Metronomic Oral Cyclophosphamide Chemotherapy Possibly Contributes to Stabilization of Disease in Patients With Metastatic Castration-Resistant Prostate Cancer: A Prospective Analysis of Consecutive Cases. Clinical Genitourinary Cancer, 2014, 12, e197-e203.	0.9	12
426	Metronomics: towards personalized chemotherapy?. Nature Reviews Clinical Oncology, 2014, 11, 413-431.	12.5	263
427	The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. Expert Review of Clinical Immunology, 2014, 10, 19-30.	1.3	48
428	Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leukemia Research, 2014, 38, 964-969.	0.4	34
429	Human regulatory <scp>T</scp> cells lack the cyclophosphamideâ€extruding transporter <scp>ABCB</scp>1 and are more susceptible to cyclophosphamideâ€induced apoptosis. European Journal of Immunology, 2014, 44, 3614-3620.	1.6	74

#	Article	IF	Citations
430	Applying extracellular vesicles based therapeutics in clinical trials â€“ an ISEV position paper. Journal of Extracellular Vesicles, 2015, 4, 30087.	5.5	1,020
431	Head and neck cancer: metronomic chemotherapy. BMC Cancer, 2015, 15, 677.	1.1	20
432	Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. Journal of Translational Medicine, 2015, 13, 204.	1.8	64
433	A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extraâ€cranial solid tumors: A Children's Oncology Group Phase I Consortium report. Pediatric Blood and Cancer, 2015, 62, 751-758.	0.8	47
434	Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget, 2015, 6, 37151-37168.	0.8	187
435	Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. Frontiers in Immunology, 2015, 6, 501.	2.2	33
436	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 516.	2.2	79
437	Brain Tumor Immunotherapy: What have We Learned so Far?. Frontiers in Oncology, 2015, 5, 98.	1.3	28
438	Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLoS ONE, 2015, 10, e0124889.	1.1	51
439	T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview. BioMed Research International, 2015, 2015, 1-9.	0.9	99
440	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Annals of Oncology, 2015, 26, 1813-1823.	0.6	219
441	Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+ T Cells. Journal of Immunology, 2015, 194, 2011-2021.	0.4	50
442	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. Expert Review of Anticancer Therapy, 2015, 15, 689-702.	1.1	10
443	Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunology, Immunotherapy, 2015, 64, 1305-1314.	2.0	31
444	Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection. Current Opinion in Virology, 2015, 13, 25-32.	2.6	19
445	Immunotherapy of Breast Cancer. Progress in Tumor Research, 2015, 42, 30-43.	0.1	27
446	Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell, 2015, 28, 690-714.	7.7	1,205
447	Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. British Journal of Cancer, 2015, 113, 1677-1686.	2.9	64

#	Article	IF	Citations
448	Insights on Peptide Vaccines in Cancer Immunotherapy. Cancer Drug Discovery and Development, 2015, , 1-27.	0.2	2
449	Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. Lung Cancer Management, 2015, 4, 249-259.	1.5	0
450	Low Noncytotoxic Concentrations of 5-Fluorouracil Have No Adverse Effects on Maturation and Function of Bone Marrow-Derived Dendritic Cells in vitro: A Potentially Safe Adjuvant for Dendritic Cell-Based Cancer Therapy. International Archives of Allergy and Immunology, 2015, 168, 122-130.	0.9	3
451	Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients. Human Immunology, 2015, 76, 187-191.	1.2	8
452	Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Letters, 2015, 358, 100-106.	3.2	194
453	Metronomic chemotherapy from rationale to clinical studies: A dream or reality?. Critical Reviews in Oncology/Hematology, 2015, 95, 46-61.	2.0	64
454	Immunotherapy for head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 299-304.	0.8	19
455	Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Medical Oncology, 2015, 32, 54.	1.2	25
456	Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cellular Immunology, 2015, 294, 54-59.	1.4	74
457	Chronodependent Effect of Interleukin-2 on Mouse Spleen Cells in the Model of Cyclophosphamide Immunosuppression. Bulletin of Experimental Biology and Medicine, 2015, 158, 471-474.	0.3	3
458	Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy and Pharmacology, 2015, 75, 821-827.	1.1	19
459	Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 85-96.	1.4	196
460	Clinical overview of metronomic chemotherapy in breast cancer. Nature Reviews Clinical Oncology, 2015, 12, 631-644.	12.5	109
461	Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice. International Immunopharmacology, 2015, 27, 95-103.	1.7	3
462	High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1/CD107a-expressing CD4-positive T cells into tumor sites. Cancer Letters, 2015, 366, 93-99.	3.2	10
463	T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response. Cancer Immunology, Immunotherapy, 2015, 64, 1369-1381.	2.0	6
464	Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication. Cancer Research, 2015, 75, 3279-3291.	0.4	47
465	Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy. Journal of Immunology, 2015, 195, 726-735.	0.4	24

#	Article	IF	Citations
466	Engineering New Approaches to Cancer Vaccines. Cancer Immunology Research, 2015, 3, 836-843.	1.6	50
467	The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. Cancer Immunology Research, 2015, 3, 436-443.	1.6	631
468	Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surfaceâ€“Associated Calreticulin. Cancer Research, 2015, 75, 1603-1614.	0.4	86
469	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
470	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Journal of Clinical Investigation, 2015, 125, 2077-2089.	3.9	111
471	Treg(s) in Cancer: Friends or Foe?. Journal of Cellular Physiology, 2015, 230, 2598-2605.	2.0	105
472	Enhanced Dendritic Cellâ€“based Immunotherapy Using Low-dose Cyclophosphamide and CD25-targeted Antibody for Transplanted Lewis Lung Carcinoma Cells. Journal of Immunotherapy, 2015, 38, 107-115.	1.2	12
473	The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy. Cancer Cell, 2015, 27, 439-449.	7.7	194
474	The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. Bone Marrow Transplantation, 2015, 50, 822-828.	1.3	17
475	Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. OncoImmunology, 2015, 4, e1001236.	2.1	22
476	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17
477	Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8⁺T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. OncoImmunology, 2015, 4, e1017702.	2.1	46
478	Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. BMC Cancer, 2015, 15, 375.	1.1	18
479	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. OncoImmunology, 2015, 4, e1026529.	2.1	79
480	Phase Iâ€<scp>II</scp> trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. British Journal of Haematology, 2015, 168, 46-54.	1.2	16
481	Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells. Scientific Reports, 2015, 5, 10665.	1.6	16
482	Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunology, Immunotherapy, 2015, 64, 1357-1367.	2.0	11
483	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75.	3.8	101

#	Article	IF	Citations
484	Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunology Research, 2015, 3, 689-701.	1.6	95
485	Interferon Alpha and Metronomic Cyclophosphamide for Metastatic Kidney Cancer: A Phase 2 Study. Journal of Interferon and Cytokine Research, 2015, 35, 367-372.	0.5	5
486	Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Medical Oncology, 2015, 32, 443.	1.2	16
487	Intermittent chemotherapy can retain the therapeutic potential of antiâ€•CD 137 antibody during the late tumorâ€bearing state. Cancer Science, 2015, 106, 9-17.	1.7	12
488	Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Cancer Chemotherapy and Pharmacology, 2015, 75, 247-254.	1.1	7
489	Oncolytic adenovirus and doxorubicinâ€based chemotherapy results in synergistic antitumor activity against softâ€tissue sarcoma. International Journal of Cancer, 2015, 136, 945-954.	2.3	51
490	Inhibition of Foxp3 in cancer cells induces apoptosis of thyroid cancer cells. Molecular and Cellular Endocrinology, 2015, 399, 228-234.	1.6	37
491	Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27â€“28 May, 2016, Rosario, Argentina. Ecancermedicalscience, 2016, 10, 672.	0.6	9
492	Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. Vaccines, 2016, 4, 38.	2.1	20
493	Combining Immunotherapies with Standard Therapies in the Treatment ofÂCancer. , 2016, , 569-580.		0
494	Oncolytic viruses as immunotherapy: progress and remaining challenges. OncoTargets and Therapy, 2016, 9, 2627.	1.0	75
495	Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic Virotherapy, 2016, Volume 6, 1-9.	6.0	8
496	Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. Journal of Immunology Research, 2016, 2016, 1-25.	0.9	49
497	Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together. Frontiers in Immunology, 2016, 7, 401.	2.2	123
499	Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS ONE, 2016, 11, e0156643.	1.1	14
500	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines, 2016, 4, 28.	2.1	372
501	Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment. OncoTargets and Therapy, 2016, Volume 9, 5101-5116.	1.0	27
503	A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anti-Cancer Drugs, 2016, 27, 106-111.	0.7	16

#	Article	IF	Citations
504	NK Cell Responses in Immunotherapy: Novel Targets and Applications. , 2016, , 79-108.		0
505	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. OncoImmunology, 2016, 5, e1207842.	2.1	29
506	Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma. Molecular Medicine Reports, 2016, 13, 2645-2654.	1.1	2
507	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 2016, 128, 2297-2306.	0.6	49
508	Therapy-activated stromal cells can dictate tumor fate. Journal of Experimental Medicine, 2016, 213, 2831-2833.	4.2	10
511	Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells. Clinical Immunology, 2016, 168, 47-54.	1.4	21
512	Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nature Reviews Clinical Oncology, 2016, 13, 659-673.	12.5	154
513	Combinatorial Cancer Immunotherapies. Advances in Immunology, 2016, 130, 251-277.	1.1	107
514	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology, 2016, 27, 1482-1492.	0.6	765
515	Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index. Breast Care, 2016, 11, 22-26.	0.8	9
516	Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clinical Immunology, 2016, 166-167, 48-58.	1.4	45
517	Immune modulation for autoimmune disorders: evolution of therapeutics. Seminars in Hematology, 2016, 53, S23-S26.	1.8	5
518	Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed. Cancer Immunology Research, 2016, 4, 377-382.	1.6	43
519	Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood, 2016, 127, 3350-3359.	0.6	33
520	Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. Oral Oncology, 2016, 62, 153-162.	0.8	8
521	Review on the immunotherapy strategies against metastatic colorectal carcinoma. Immunotherapy, 2016, 8, 1245-1261.	1.0	8
522	CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity. Cancer Research, 2016, 76, 6483-6494.	0.4	64
523	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1599-1611.	5.1	181

#	Article	IF	Citations
524	Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology. SpringerBriefs in Immunology, 2016, , .	0.1	0
525	Combinatorial Polymeric Conjugated Micelles with Dual Cytotoxic and Antiangiogenic Effects for the Treatment of Ovarian Cancer. Chemistry of Materials, 2016, 28, 6068-6079.	3.2	16
526	Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. Cancer Research, 2016, 76, 5983-5993.	0.4	46
527	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Therapeutic Advances in Medical Oncology, 2016, 8, 360-374.	1.4	37
528	Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells. Journal of Experimental Medicine, 2016, 213, 2967-2988.	4.2	135
529	Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells. Cytotherapy, 2016, 18, 1410-1421.	0.3	26
530	INFÎ±-2b inhibitory effects on CD4+CD25+FOXP3+ regulatory T cells in the tumor microenvironment of C57BL/6Âj mice with melanoma xenografts. BMC Cancer, 2016, 16, 397.	1.1	15
531	Pharmacokinetics and Pharmacogenetics of Metronomics. , 2016, , 189-207.		0
532	The influence of hydro-ethanolic extract of Portulaca oleracea L. on Th1/Th2 balance in isolated human lymphocytes. Journal of Ethnopharmacology, 2016, 194, 1112-1121.	2.0	58
533	Immunological Mechanisms Underneath the Efficacy of Cancer Therapy. Cancer Immunology Research, 2016, 4, 895-902.	1.6	134
534	Metronomic Chemotherapy for Metastatic Breast Cancer â€“ a Systematic Review of the Literature. Geburtshilfe Und Frauenheilkunde, 2016, 76, 525-534.	0.8	27
535	A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic) Tj ETQq1 1 0.784314 rgBT /Overl	3.2	125
536	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. Breast Care, 2016, 11, 102-107.	0.8	35
537	Immunotherapy for Head and Neck Squamous Cell Carcinoma. Current Oral Health Reports, 2016, 3, 74-81.	0.5	6
539	Adoptive Cellular Therapy (ACT) for Cancer Treatment. Advances in Experimental Medicine and Biology, 2016, 909, 169-239.	0.8	14
540	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 387-394.	0.2	11
541	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
542	Gene therapy approaches against cancer usingin vivoandex vivogene transfer of interleukin-12. Immunotherapy, 2016, 8, 179-198.	1.0	29

#	Article	IF	Citations
543	Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials, 2016, 83, 308-320.	5.7	107
544	Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. Cancer Chemotherapy and Pharmacology, 2016, 77, 365-374.	1.1	41
545	Immune Therapy. Advances in Experimental Medicine and Biology, 2016, 893, 59-90.	0.8	1
546	Regulatory T cells in the immunotherapy of melanoma. Tumor Biology, 2016, 37, 77-85.	0.8	17
548	Low dose cyclophosphamide: Mechanisms of T cell modulation. Cancer Treatment Reviews, 2016, 42, 3-9.	3.4	117
549	Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	1.1	10
550	Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. OncoImmunology, 2016, 5, e1066062.	2.1	55
551	Combinatorial immunotherapy strategies for hepatocellular carcinoma. Current Opinion in Immunology, 2016, 39, 103-113.	2.4	52
552	Eco-evolution of cancer resistance. Science Translational Medicine, 2016, 8, 327fs5.	5.8	30
553	Methotrexate up-regulates ecto-5â€²-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment. Purinergic Signalling, 2016, 12, 303-312.	1.1	33
554	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. Journal of Translational Medicine, 2016, 14, 58.	1.8	18
555	Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nature Reviews Cancer, 2016, 16, 219-233.	12.8	580
556	Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1023-1031.	2.5	94
557	A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer. Cancer Immunology, Immunotherapy, 2016, 65, 151-160.	2.0	57
558	Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. OncoImmunology, 2016, 5, e1078057.	2.1	29
559	Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients. Veterinary and Comparative Oncology, 2017, 15, 594-605.	0.8	10
560	Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs. Veterinary and Comparative Oncology, 2017, 15, 421-430.	0.8	12
561	Immune Checkpoint Inhibitors in Lung Cancer â€“ An Unheralded Opportunity?. Clinical Oncology, 2017, 29, 207-217.	0.6	6

#	Article	IF	Citations
562	Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancerâ€bearing dogs: a retrospective study. Journal of Small Animal Practice, 2017, 58, 227-230.	0.5	11
563	Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia, 2017, 31, 2181-2190.	3.3	188
564	Translational nanoparticle engineering for cancer vaccines. OncoImmunology, 2017, 6, e1290036.	2.1	35
565	Metronomic and metronomic-like therapies in neuroendocrine tumors â€“ Rationale and clinical perspectives. Cancer Treatment Reviews, 2017, 55, 46-56.	3.4	7
566	Role of vascular normalization in benefit from metronomic chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1994-1999.	3.3	136
567	Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Letters, 2017, 400, 282-292.	3.2	116
568	Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?. Trends in Cancer, 2017, 3, 319-325.	3.8	52
569	Immunotherapy for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2017, 17, 797-812.	1.4	12
570	Current achievements and future perspectives of metronomic chemotherapy. Investigational New Drugs, 2017, 35, 359-374.	1.2	25
571	Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4+CD25bri regulatory T cells. Immunology Letters, 2017, 181, 36-44.	1.1	4
572	Immunotherapeutic properties of chemotherapy. Current Opinion in Pharmacology, 2017, 35, 83-88.	1.7	30
573	A randomized phase <scp>II</scp> trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer Science, 2017, 108, 838-845.	1.7	30
574	Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer â€“ a Systematic Review of the Literature. Geburtshilfe Und Frauenheilkunde, 2017, 77, 142-148.	0.8	3
575	Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents. International Review of Cell and Molecular Biology, 2017, 330, 115-156.	1.6	22
576	Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Letters, 2017, 400, 243-251.	3.2	26
577	Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. British Journal of Cancer, 2017, 116, 324-334.	2.9	35
578	Regulatory T cells in cancer immunotherapy. Cell Research, 2017, 27, 109-118.	5.7	1,212
579	Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. Scientific Reports, 2017, 7, 14186.	1.6	32

#	Article	IF	Citations
580	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. OncoImmunology, 2017, 6, e1386829.	2.1	209
581	Tumor Dormancy, Angiogenesis and Metronomic Chemotherapy. Cancer Drug Discovery and Development, 2017, , 31-49.	0.2	3
582	Immunological effects of everolimus in patients with metastatic renal cell cancer. International Journal of Immunopathology and Pharmacology, 2017, 30, 341-352.	1.0	21
583	Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. Journal of Leukocyte Biology, 2017, 102, 1347-1356.	1.5	40
584	Immune recognition of irradiated cancer cells. Immunological Reviews, 2017, 280, 220-230.	2.8	73
585	Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunological Reviews, 2017, 280, 126-148.	2.8	325
586	The renaissance of antiâ€neoplastic immunity from tumor cell demise. Immunological Reviews, 2017, 280, 194-206.	2.8	53
587	Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. Journal of the National Cancer Institute, 2017, 109, .	3.0	31
588	Effect of Modified Vaccinia Ankaraâ€“5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, e172579.	3.4	51
589	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Seminars in Immunology, 2017, 31, 64-75.	2.7	110
590	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas, 2017, 46, 1180-1187.	0.5	47
591	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 6771-6780.	3.2	114
592	Tumor Dormancy and Recurrence. Cancer Drug Discovery and Development, 2017, , .	0.2	2
593	Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. OncoImmunology, 2017, 6, e1338238.	2.1	19
594	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
595	Conditioning neoadjuvant therapies for improved immunotherapy of cancer. Biochemical Pharmacology, 2017, 145, 12-17.	2.0	11
596	Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles. Journal of Controlled Release, 2017, 267, 203-213.	4.8	35
597	Ovarian Cancers. , 2017, , .		1

#	Article	IF	Citations
598	Metronomic chemotherapy in head and neck cancer. Cancer Letters, 2017, 400, 219-222.	3.2	5
599	Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study. Cancer Letters, 2017, 400, 205-218.	3.2	18
600	Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 204-211.	0.7	11
601	Chemotherapy changes cytotoxic activity of NK-cells in cancer patients. AIP Conference Proceedings, 2017, , .	0.3	0
602	The Biology of Inflammatory Breast Cancer. Breast, 2017, 36, S24-S25.	0.9	0
603	Chest Wall Disease: The Clinical Continuum between Inflammatory and Lymphangitic Breast Cancer. Breast, 2017, 36, S25.	0.9	0
605	Developing T-cell therapies for lymphoma without receptor engineering. Hematology American Society of Hematology Education Program, 2017, 2017, 622-631.	0.9	2
606	Developing T-cell therapies for lymphoma without receptor engineering. Blood Advances, 2017, 1, 2579-2590.	2.5	7
607	Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?. Frontiers in Pharmacology, 2017, 8, 732.	1.6	2
608	A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 2134.	1.8	55
609	The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression. , 2017, , 33-61.		3
610	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. BioMed Research International, 2017, 2017, 1-10.	0.9	6
611	Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Journal of Immunology Research, 2017, 2017, 1-16.	0.9	18
612	The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers. Journal of Immunology Research, 2017, 2017, 1-21.	0.9	17
613	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. OncoTargets and Therapy, 2017, Volume 10, 3697-3708.	1.0	6
614	The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis. PLoS ONE, 2017, 12, e0173693.	1.1	30
615	An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer. Applied Cancer Research, 2017, 37, .	1.0	3
616	Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biology and Medicine, 2017, 14, 121.	1.4	8

#	Article	IF	Citations
617	Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer. Oncotarget, 2017, 8, 84248-84257.	0.8	18
618	Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Letters, 2018, 419, 210-221.	3.2	251
619	Tâ€cell modulation by cyclophosphamide for tumour therapy. Immunology, 2018, 154, 62-68.	2.0	53
620	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. Molecular Cancer Therapeutics, 2018, 17, 869-882.	1.9	20
621	Present status and future perspective of peptideâ€based vaccine therapy for urological cancer. Cancer Science, 2018, 109, 550-559.	1.7	42
622	Chemotherapy alters the increased numbers of myeloid-derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia. Immunopharmacology and Immunotoxicology, 2018, 40, 158-167.	1.1	29
623	Cell death-based treatment of lung adenocarcinoma. Cell Death and Disease, 2018, 9, 117.	2.7	434
624	Immunotherapy using regulatory T cells in cancer suggests more flavors of hypersensitivity type IV. Immunotherapy, 2018, 10, 213-219.	1.0	0
625	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. Pancreas, 2018, 47, 142-157.	0.5	19
626	Next-generation immunotherapies for lymphoma: one foot in the future. Annals of Oncology, 2018, 29, 588-601.	0.6	13
627	Cancer Vaccines for HPV Malignancies. , 2018, , 263-274.		1
628	Strategies to Reduce Intratumoral Regulatory T Cells. , 2018, , 483-506.		1
629	Plasmacytoid DC/Regulatory T Cell Interactions at the Center of an Immunosuppressive Network in Breast and Ovarian Tumors. , 2018, , 143-161.		0
630	Combined Immunotherapy with Conventional Cancer Treatments. , 2018, , 115-123.		0
631	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. British Journal of Cancer, 2018, 118, 1329-1336.	2.9	75
632	Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases. Gynecologic Oncology Reports, 2018, 24, 57-60.	0.3	5
634	Cyclophosphamide-modified murine peritoneal macrophages induce CD4+ T contrasuppressor cells that protect contact sensitivity T effector cells from suppression. Pharmacological Reports, 2018, 70, 796-803.	1.5	1
635	Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research, 2018, 24, 3014-3025.	3.2	64

#	Article	IF	Citations
636	Auraptene regulates Th 1 /Th 2 /T Reg balances, NF-ÎºB nuclear localization and nitric oxide production in normal and Th 2 provoked situations in human isolated lymphocytes. Phytomedicine, 2018, 43, 1-10.	2.3	39
637	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica, 2018, 103, e368-e371.	1.7	43
638	The emerging world of breast cancer immunotherapy. Breast, 2018, 37, 200-206.	0.9	39
639	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. JAMA Oncology, 2018, 4, 93.	3.4	303
640	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clinical Breast Cancer, 2018, 18, e143-e149.	1.1	15
641	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist, 2018, 23, 71-83.	1.9	45
642	Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. Clinical Breast Cancer, 2018, 18, e135-e142.	1.1	17
643	Review of cancer treatment with immune checkpoint inhibitors. Wiener Klinische Wochenschrift, 2018, 130, 85-91.	1.0	102
644	Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!. Blood Reviews, 2018, 32, 203-224.	2.8	21
645	Lack of MHC class II molecules favors CD8⁺T-cell infiltration into tumors associated with an increased control of tumor growth. OncoImmunology, 2018, 7, e1404213.	2.1	15
647	Combinatorial Immunotherapy and Chemotherapy. Current Cancer Research, 2018, , 199-218.	0.2	4
648	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast Cancer Research and Treatment, 2018, 168, 57-67.	1.1	15
652	From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis. International Journal of Molecular Sciences, 2018, 19, 3584.	1.8	10
653	Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. OncoImmunology, 2018, 7, e1500671.	2.1	31
654	The failure of radical treatments to cure cancer: can less deliver more?. , 2018, 6, 69-76.	1.4	10
655	Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma. Journal of Translational Medicine, 2018, 16, 349.	1.8	19
656	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Frontiers in Oncology, 2018, 8, 532.	1.3	27
657	Effects of Chemotherapy on the Leucocyte Infiltration in Periodontal Tissues of Cancer Patients: A Preliminary Study. Internal Medicine: Open Access, 2018, 08, .	0.0	0

#	Article	IF	Citations
658	Regulatory T cells in the treatment of disease. Nature Reviews Drug Discovery, 2018, 17, 823-844.	21.5	224
659	Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Cytotherapy, 2018, 20, 1309-1323.	0.3	16
660	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Frontiers in Immunology, 2018, 9, 2265.	2.2	107
661	Role of Regulatory T Cells in Tumor-Bearing Mice Treated with Allo-Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation. Journal of Immunology Research, 2018, 2018, 1-7.	0.9	3
662	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends in Immunology, 2018, 39, 900-920.	2.9	56
663	Low-dose cyclophosphamide depletes circulating naÃ¯ve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. OncoImmunology, 2018, 7, e1474318.	2.1	30
664	Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients. Breast Care, 2018, 13, 272-276.	0.8	16
665	Chemotherapy Combines Effectively with Antiâ€“PD-L1 Treatment and Can Augment Antitumor Responses. Journal of Immunology, 2018, 201, 2273-2286.	0.4	38
666	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1451-1463.	0.9	5
667	Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. Medical Oncology, 2018, 35, 136.	1.2	5
668	Disappearance of bone metastases in chemotherapyâ€‘resistant gastric cancer treated with antigen peptideâ€‘pulsed dendritic cellâ€‘activated cytotoxic T lymphocyte immunotherapy: A case report. Oncology Letters, 2018, 16, 875-881.	0.8	4
669	Inflammatory breast cancer and chest wall disease: The oncologist perspective. European Journal of Surgical Oncology, 2018, 44, 1142-1147.	0.5	6
670	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
671	Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma. Clinical Cancer Research, 2018, 24, 5685-5696.	3.2	76
672	The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one. Cancer Treatment Reviews, 2018, 70, 41-46.	3.4	21
673	Effect of dendritic cellâ€“based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis. Cytotherapy, 2018, 20, 975-989.	0.3	27
674	Potentiating cancer vaccine efficacy in liver cancer. OncoImmunology, 2018, 7, e1488564.	2.1	26
675	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Management and Research, 2018, Volume 10, 931-940.	0.9	10

#	Article	IF	Citations
676	High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with Treg depletion. Cancer Immunology, Immunotherapy, 2018, 67, 1545-1558.	2.0	13
677	Regulatory T Cells As Potential Targets for HIV Cure Research. Frontiers in Immunology, 2018, 9, 734.	2.2	51
678	Docetaxel Down-Regulates PD-1 Expression via STAT3 in T Lymphocytes. Clinical Lung Cancer, 2018, 19, e675-e683.	1.1	12
679	Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector,) Tj ETQq1 1 0.784314 rgBT /Overlock Cancer, 2018, 18, 123.	1.1	13
680	Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?. Current Cancer Drug Targets, 2018, 18, 139-152.	0.8	7
681	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Frontiers in Immunology, 2018, 9, 1739.	2.2	174
682	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT) Tj ETQq0 0 0 rgBT /Overlock 1 cyclophosphamide. Clinical and Translational Radiation Oncology, 2018, 12, 47-52.	0.9	12
683	Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Letters, 2018, 432, 28-37.	3.2	52
684	Immunomodulatory Drugs and Monoclonal Antibodies. , 2018, , 85-100.		1
685	Immunogenic effects of chemotherapy-induced tumor cell death. Genes and Diseases, 2018, 5, 194-203.	1.5	219
686	Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs. Medical Oncology, 2019, 36, 80.	1.2	11
687	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. Frontiers in Immunology, 2019, 10, 1654.	2.2	101
688	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncology, The, 2019, 20, e417-e433.	5.1	89
689	Immunogenic cell death in a combined synergic gene- and immune-therapy against cancer. OncoImmunology, 2019, 8, e1667743.	2.1	13
690	Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. Chemical Society Reviews, 2019, 48, 5506-5526.	18.7	209
691	Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity. Nano Letters, 2019, 19, 8333-8341.	4.5	51
692	A preliminary Study on the Effect of Head and Neck Chemoradiotherapy on Systematic Immunity. Dose-Response, 2019, 17, 155932581988418.	0.7	10
693	Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer. International Journal of Molecular Sciences, 2019, 20, 5438.	1.8	5

#	Article	IF	Citations
694	Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2019, 8, 1224.	1.0	10
695	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. European Journal of Cancer, 2019, 119, 151-157.	1.3	103
696	Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle. Journal of Controlled Release, 2019, 311-312, 85-95.	4.8	41
697	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. Journal of Clinical Investigation, 2019, 129, 2056-2070.	3.9	159
698	The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma . Cancer Management and Research, 2019, Volume 11, 7455-7472.	0.9	37
699	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Research, 2019, 21, 108.	2.2	21
700	Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. PLoS ONE, 2019, 14, e0222580.	1.1	7
701	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer: Targets and Therapy, 2019, Volume 11, 53-69.	1.0	63
702	Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. Advances in Cancer Research, 2019, 144, 193-261.	1.9	19
703	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. Frontiers in Immunology, 2019, 10, 1181.	2.2	20
704	The 100 top-cited studies in cancer immunotherapy. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 2282-2292.	1.9	26
705	Recent advances in the study of regulatory T cells in gastric cancer. International Immunopharmacology, 2019, 73, 560-567.	1.7	27
706	Regulatory T cells as therapeutic targets and mediators. International Reviews of Immunology, 2019, 38, 183-203.	1.5	10
707	Ex vivo expanded patient-derived Î³Î´ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model. OncoImmunology, 2019, 8, 1593804.	2.1	20
708	Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks. Journal of Clinical Medicine, 2019, 8, 702.	1.0	13
709	Interaction of tumor-associated macrophages and cancer chemotherapy. OncoImmunology, 2019, 8, e1596004.	2.1	205
710	Recent advances in triple negative breast cancer: the immunotherapy era. BMC Medicine, 2019, 17, 90.	2.3	267
711	Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments. Journal of Controlled Release, 2019, 305, 130-154.	4.8	40

#	Article	IF	Citations
712	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. International Journal of Molecular Sciences, 2019, 20, 1903.	1.8	15
713	Immunotherapy in hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 291-297.	0.6	66
714	Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience. Journal of Oncology, 2019, 2019, 1-31.	0.6	83
715	Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. OncoImmunology, 2019, 8, e1570778.	2.1	19
716	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Molecular Therapy - Oncolytics, 2019, 13, 67-81.	2.0	44
717	The Contribution of the Immune System in Bone Metastasis Pathogenesis. International Journal of Molecular Sciences, 2019, 20, 999.	1.8	67
718	Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. Cancer Biology and Therapy, 2019, 20, 941-947.	1.5	15
719	Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Anticancer Research, 2019, 39, 1749-1760.	0.5	30
720	Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment. JCO Clinical Cancer Informatics, 2019, 3, 1-20.	1.0	52
721	Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Letters, 2019, 454, 191-203.	3.2	60
722	Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?. , 2019, 7, 85.		175
723	Harnessing the Immune System in HER2+ Disease. , 2019, , 213-230.		0
724	Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. Frontiers in Immunology, 2019, 10, 8.	2.2	156
725	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. Journal of Oncology, 2019, 2019, 1-18.	0.6	76
726	Addition of Cyclophosphamide â€œOn Demandâ€•to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myelomaâ€”A Retrospective Review of a Single-center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e195-e203.	0.2	4
727	Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma. Vaccine, 2019, 37, 1565-1576.	1.7	14
728	Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. Acta Biomaterialia, 2019, 88, 1-14.	4.1	29
729	Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. Cancer Immunology, Immunotherapy, 2019, 68, 787-798.	2.0	2

#	Article	IF	Citations
730	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of Translational Medicine, 2019, 17, 391.	1.8	42
731	Cancer Immunotherapy. , 2019, , 231-250.		0
732	Molecular/Targeted Therapy of Cancer. , 2019, , 251-285.		0
733	Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews, 2019, 38, 595-610.	2.7	65
734	The pro-tumorigenic host response to cancer therapies. Nature Reviews Cancer, 2019, 19, 667-685.	12.8	135
735	Repurposing Food and Drug Administrationâ€“Approved Drugs to Promote Antitumor Immunity. Cancer Journal (Sudbury, Mass), 2019, 25, 88-99.	1.0	5
736	Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. Journal of Immunotherapy, 2019, 42, 180-188.	1.2	17
737	The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction. Cancers, 2019, 11, 2.	1.7	27
738	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery, 2019, 18, 197-218.	21.5	2,005
739	Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. Advances in Therapy, 2019, 36, 381-406.	1.3	19
740	Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 319-329.	2.0	11
741	Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Annals of Oncology, 2019, 30, 219-235.	0.6	340
742	Natural modulators of the hallmarks of immunogenic cell death. Biochemical Pharmacology, 2019, 162, 55-70.	2.0	32
743	Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. , 2019, 7, 10.		66
744	The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial. Cancer Immunology, Immunotherapy, 2019, 68, 503-515.	2.0	26
745	Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opinion on Biological Therapy, 2019, 19, 225-232.	1.4	22
746	Regulatory T cells. , 2019, , 33-45.		0
747	The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Medical Oncology, 2020, 37, 2.	1.2	145

#	Article	IF	Citations
748	Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma â€“ a case report. International Journal of Hyperthermia, 2020, 37, 55-65.	1.1	8
749	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. Cancer Letters, 2020, 473, 25-32.	3.2	40
750	Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbineâ€“atezolizumab combination for stage-IV non-small-cell lung cancer â€“ VinMetAtezo trial, (GFPC^{â€¡} 04-2017). Future Oncology, 2020, 16, 5-10.	1.1	13
751	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology, 2020, 17, 13-26.	4.8	76
752	Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. International Immunopharmacology, 2020, 78, 106087.	1.7	33
753	Blocking inflammation to improve immunotherapy of advanced cancer. Immunology, 2020, 159, 357-364.	2.0	34
754	Metronomic cyclophosphamide induces regulatory T cells depletion and PSAâ€specific T cells reactivation in patients with biochemical recurrent prostate cancer. International Journal of Cancer, 2020, 147, 1199-1205.	2.3	10
755	Analysis of chemotherapy effect on the second primary malignancy for head and neck cancer patients by a nomogram based on SEER database. Cancer Medicine, 2020, 9, 8029-8042.	1.3	11
756	Molecular mechanisms of breast cancer chemoresistance by immune checkpoints. Life Sciences, 2020, 263, 118604.	2.0	9
757	Chemotherapy but Not the Tumor Draining Lymph Nodes Determine the Immunotherapy Response in Secondary Tumors. IScience, 2020, 23, 101056.	1.9	15
758	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Research, 2020, 30, 364-375.	0.6	42
759	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. Translational Lung Cancer Research, 2020, 9, 2082-2096.	1.3	4
760	Dexosomes as a cell-free vaccine for cancer immunotherapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 258.	3.5	79
761	Development of Therapeutic Vaccines for Ovarian Cancer. Vaccines, 2020, 8, 657.	2.1	15
762	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews Clinical Oncology, 2020, 17, 725-741.	12.5	701
763	Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery, 2020, 19, 635-652.	21.5	148
764	Combinatorial drug therapy in cancer - New insights. Life Sciences, 2020, 258, 118134.	2.0	31
765	Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. Npj Breast Cancer, 2020, 6, 29.	2.3	26

#	Article	IF	Citations
766	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. , 2020, 8, e000342.		32
767	PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5337.	1.8	26
768	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells, 2020, 9, 1727.	1.8	8
769	Tumor-Associated Macrophage Status in Cancer Treatment. Cancers, 2020, 12, 1987.	1.7	101
770	Toxicity of a methotrexate metronomic schedule in Wistar rats. Research in Veterinary Science, 2020, 132, 379-385.	0.9	4
771	Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer . International Journal of Nanomedicine, 2020, Volume 15, 7719-7743.	3.3	12
772	Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. Cancers, 2020, 12, 2637.	1.7	40
773	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Seminars in Cancer Biology, 2021, 77, 127-143.	4.3	59
774	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). OncoImmunology, 2020, 9, 1806680.	2.1	11
775	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 2208-2215.	0.6	7
776	Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors. Cancer Gene Therapy, 2020, 28, 1188-1197.	2.2	3
777	The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment. Journal of Clinical Medicine, 2020, 9, 3912.	1.0	6
778	Target the Host, Kill the Bug; Targeting Host Respiratory Immunosuppressive Responses as a Novel Strategy to Improve Bacterial Clearance During Lung Infection. Frontiers in Immunology, 2020, 11, 767.	2.2	9
779	Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. BMC Cancer, 2020, 20, 445.	1.1	11
780	Novel Forms of Immunomodulation for Cancer Therapy. Trends in Cancer, 2020, 6, 518-532.	3.8	17
781	Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance. Frontiers in Immunology, 2020, 11, 1376.	2.2	23
782	Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death and Disease, 2020, 11, 361.	2.7	30
783	Targeting Inhibition of Foxp3 by MMP2/9 Sensitive Short Peptide Linked P60 Fusion Protein 6(P60â€MMPs) to Enhance Antitumor Immunity. Macromolecular Bioscience, 2020, 20, 2000098.	2.1	5

#	Article	IF	Citations
784	Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis. Frontiers in Immunology, 2020, 11, 806.	2.2	16
785	Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. Pharmaceutics, 2020, 12, 524.	2.0	22
786	Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Lung Cancer, 2020, 146, 86-96.	0.9	14
787	Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology, 2020, 108, 1455-1489.	1.5	22
788	Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. Frontiers in Oncology, 2020, 10, 777.	1.3	6
789	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. Frontiers in Oncology, 2020, 10, 899.	1.3	44
790	Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion. Journal of Controlled Release, 2020, 322, 13-30.	4.8	25
791	Metronomic anti-angiogenesis: The ideal companion of pH-centered treatments. , 2020, , 467-487.		0
792	Achievements and challenges in the use of metronomics for the treatment of breast cancer. Biochemical Pharmacology, 2020, 175, 113909.	2.0	10
793	Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All. Trends in Cancer, 2020, 6, 819-828.	3.8	20
794	ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer. Journal of Translational Medicine, 2020, 18, 252.	1.8	16
795	How does autophagy affect tumor-infiltrating immune cells?. , 2020, , 75-84.		0
796	ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. Journal of Translational Medicine, 2020, 18, 269.	1.8	26
797	The effects of CTX damage or inhibition of bone marrow hematopoiesis and GM-CSF stimulation of bone marrow hematopoiesis on the peripheral blood TCRÎ² CDR3 repertoire of BALB/c mice. Immunopharmacology and Immunotoxicology, 2020, 42, 110-118.	1.1	2
798	Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer, 2020, 2, zcaa002.	1.6	142
799	Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-Î² Signaling Pathway. International Journal of Molecular Sciences, 2020, 21, 957.	1.8	22
800	Modulation of regulatory T cell function and stability by co-inhibitory receptors. Nature Reviews Immunology, 2020, 20, 680-693.	10.6	127
801	Red Wine Extract Disrupts Th17 Lymphocyte Differentiation in a Colorectal Cancer Context. Molecular Nutrition and Food Research, 2020, 64, 1901286.	1.5	10

#	Article	IF	Citations
802	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. Cells, 2020, 9, 940.	1.8	8
803	Human microbiome and prostate cancer development: current insights into the prevention and treatment. Frontiers of Medicine, 2021, 15, 11-32.	1.5	17
804	Immuno-modulatory effects of methanolic extract of Ferula szowitsiana on isolated human Th1/Th2/Treg cytokines levels, and their genes expression and nitric oxide production. Cytokine, 2021, 138, 155387.	1.4	6
805	Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer. JAMA Oncology, 2021, 7, 78.	3.4	103
806	Efficacy of cancer vaccines in selected gynaecological breast and ovarianÂcancers: A 20-year systematic review and meta-analysis. European Journal of Cancer, 2021, 142, 63-82.	1.3	19
807	Efficacy and safety of oral metronomic etoposide in adult patients with metastatic osteosarcoma. Cancer Medicine, 2021, 10, 230-236.	1.3	7
808	Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress. Expert Review of Anticancer Therapy, 2021, 21, 71-79.	1.1	11
809	Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. OncoImmunology, 2021, 10, 1859263.	2.1	13
810	Immunochemo combination therapy in cancer treatment. , 2021, , 255-273.		0
811	Ultrasound-Mediated Remotely Controlled Nanovaccine Delivery for Tumor Vaccination and Individualized Cancer Immunotherapy. Nano Letters, 2021, 21, 1228-1237.	4.5	61
812	Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers, 2021, 13, 711.	1.7	18
813	A phase 1b clinical trial optimizing regulatory T cell depletion in combination with platinum-based chemotherapy in thoracic cancers. Expert Review of Anticancer Therapy, 2021, 21, 465-474.	1.1	1
814	Immune Therapy Resistance and Immune Escape of Tumors. Cancers, 2021, 13, 551.	1.7	32
815	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Frontiers in Immunology, 2020, 11, 615240.	2.2	59
816	Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy. Critical Reviews in Oncology/Hematology, 2021, 159, 103226.	2.0	19
817	Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. Vaccines, 2021, 9, 235.	2.1	3
818	Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Frontiers in Immunology, 2021, 12, 653358.	2.2	19
819	Therapeutic applications of the cancer immunoediting hypothesis. Seminars in Cancer Biology, 2022, 78, 63-77.	4.3	29

#	Article	IF	Citations
820	Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. Journal of Nanobiotechnology, 2021, 19, 110.	4.2	16
821	Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?. Geriatrics (Switzerland), 2021, 6, 42.	0.6	2
822	Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances, 2021, 5, 2196-2215.	2.5	56
823	Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 302-318.	2.6	40
824	Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC. Cancers, 2021, 13, 1901.	1.7	13
825	Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens. Current Medicinal Chemistry, 2021, 28, 2114-2136.	1.2	6
826	Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. Frontiers in Oncology, 2021, 11, 559161.	1.3	34
827	Current and Novel Alkylators in Multiple Myeloma. Cancers, 2021, 13, 2465.	1.7	12
828	The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Cancer Science, 2021, 112, 2895-2904.	1.7	9
829	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 650486.	2.2	26
830	Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study. Frontiers in Immunology, 2021, 12, 632547.	2.2	13
831	Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1037-1044.	1.2	8
832	Lack of Specific Regulatory T Cell Depletion and Cytoreduction Associated with Extensive Toxicity After Administration of Low and High Doses of Cyclophosphamide. AIDS Research and Human Retroviruses, 2022, 38, 45-49.	0.5	1
833	Comparative efficacy and safety of metronomic chemotherapy in breast cancer. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	0
834	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSÃ©-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, 2021, 150, 53-62.	1.3	33
835	Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer and Metastasis Reviews, 2021, 40, 537-547.	2.7	58
836	Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies. Cancers, 2021, 13, 2821.	1.7	26
837	Cancer immunotherapy: itâ€™s time to better predict patientsâ€™ response. British Journal of Cancer, 2021, 125, 927-938.	2.9	63

#	Article	IF	Citations
838	Metronomic Therapy in Oral Squamous Cell Carcinoma. Journal of Clinical Medicine, 2021, 10, 2818.	1.0	5
839	Relationship between stromal regulatory T cells and the response to neoadjuvant chemotherapy for locally advanced rectal cancer. Surgery Today, 2022, 52, 198-206.	0.7	3
840	Vinorelbine in treatment of non-small cell lung cancer. Medical Alphabet, 2021, , 8-15.	0.0	0
843	DC-Derived Exosomes for Cancer Immunotherapy. Cancers, 2021, 13, 3667.	1.7	43
844	Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-d-l-Lactide-Co-Glycolide (PLGA) Nanofibers. Cancers, 2021, 13, 3350.	1.7	16
845	Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity. Advanced Drug Delivery Reviews, 2021, 179, 113920.	6.6	18
846	A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer. Clinical Breast Cancer, 2021, 21, e332-e339.	1.1	3
847	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines, 2021, 9, 1075.	1.4	46
848	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. Journal of Clinical Medicine, 2021, 10, 3940.	1.0	10
849	Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. Coordination Chemistry Reviews, 2021, 442, 214009.	9.5	29
850	The promise and perils of immunotherapy. Blood Advances, 2021, 5, 3709-3725.	2.5	23
851	Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Breast Cancer Research and Treatment, 2021, 190, 415-424.	1.1	6
852	Aptamer-mediated transcriptional gene silencing of Foxp3 inhibits regulatory TÂcells and potentiates antitumor response. Molecular Therapy - Nucleic Acids, 2021, 25, 143-151.	2.3	4
853	Cyclophosphamide loaded thermo-responsive hydrogel system synergize with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner. Bioactive Materials, 2021, 6, 3036-3048.	8.6	36
854	Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?. International Journal of Molecular Sciences, 2021, 22, 10672.	1.8	5
855	The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. Life Sciences, 2021, 284, 119132.	2.0	26
856	Upcoming immunotherapeutic combinations for B-cell lymphoma. Immunotherapy Advances, 2021, 1, .	1.2	3
857	Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?. Cancers, 2021, 13, 360.	1.7	25

#	Article	IF	Citations
858	Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man. , 2008, , 277-296.		1
859	Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer. Recent Results in Cancer Research, 2010, 180, 165-183.	1.8	29
860	Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective. , 2014, , 3-21.		2
861	Effects of Metronomic Chemotherapy on Immunity. , 2014, , 39-51.		1
862	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer. , 2014, , 291-327.		1
863	The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment. , 2010, , 243-262.		10
864	Effect of Chemotherapy on the Tumor Microenvironment and Anti-tumor Immunity. , 2013, , 1-28.		3
865	Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma. HemaSphere, 2020, 4, e350.	1.2	29
869	CX3CR1 identifies PD-1 therapyâ€“responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight, 2018, 3, .	2.3	106
870	Tregs and rethinking cancer immunotherapy. Journal of Clinical Investigation, 2007, 117, 1167-1174.	3.9	464
871	Dendritic cellâ€“derived exosomes for cancer therapy. Journal of Clinical Investigation, 2016, 126, 1224-1232.	3.9	427
872	A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 4520-4520.	0.6	3
873	The Role of Tregs in Human Glioma Patients and their Inhibition with a Novel STAT-3 Inhibitor. Neurosurgery, 2008, 62, 1423.	0.6	12
874	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. PLoS ONE, 2009, 4, e6910.	1.1	64
875	A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma. PLoS ONE, 2012, 7, e48424.	1.1	52
876	Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response. PLoS ONE, 2013, 8, e83384.	1.1	80
877	Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment. PLoS ONE, 2014, 9, e109992.	1.1	33
878	Regulatory T Cells in Endemic Burkitt Lymphoma Patients Are Associated with Poor Outcomes: A Prospective, Longitudinal Study. PLoS ONE, 2016, 11, e0167841.	1.1	14

#	Article	IF	Citations
879	Knowing the tumour microenvironment to optimise immunotherapy. Acta Otorhinolaryngologica Italica, 2019, 39, 2-8.	0.7	16
880	Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. Oncotarget, 2016, 7, 59754-59765.	0.8	4
881	Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. Oncotarget, 2017, 8, 5219-5232.	0.8	15
882	Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget, 2017, 8, 19803-19813.	0.8	30
883	Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer. Oncotarget, 2017, 8, 79527-79536.	0.8	2
884	Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28â˜ T-cells. Oncotarget, 2017, 8, 98200-98214.	0.8	15
885	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. Oncotarget, 2018, 9, 3576-3589.	0.8	19
886	Immunological monitoring for prediction of clinical response to antitumor vaccine therapy. Oncotarget, 2018, 9, 24381-24390.	0.8	2
887	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. Oncotarget, 2018, 9, 34009-34021.	0.8	17
888	Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. Oncotarget, 2019, 10, 7220-7237.	0.8	11
889	Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models. Oncotarget, 2020, 11, 3048-3060.	0.8	5
890	The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget, 2016, 7, 29794-29803.	0.8	48
891	Future paradigms for precision oncology. Oncotarget, 2016, 7, 46813-46831.	0.8	23
892	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
893	Antitumor activity of total flavonoids from Tetrastigma hemsleyanum Diels et Gilg is associated with the inhibition of regulatory T cells in mice. OncoTargets and Therapy, 2014, 7, 947.	1.0	43
894	Terapia metronÃ³mica en el manejo del paciente veterinario con cÃ¡ncer. CES Medicina Veterinaria Y Zootecnia, 2017, 12, 195-210.	0.1	1
895	A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response. Current Gene Therapy, 2014, 14, 236-246.	0.9	16
896	The effect of alpha linolenic acid on tracheal responsiveness, lung inflammation, and immune markers in sensitized rats. Iranian Journal of Basic Medical Sciences, 2019, 22, 255-261.	1.0	8

#	Article	IF	Citations
897	Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies. Future Oncology, 2013, 9, 469-472.	1.1	11
898	Neoadjuvant immunotherapy in breast cancer: a paradigm shift?. Ecancermedicalscience, 2020, 14, 1147.	0.6	12
899	Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience, 2020, 14, 1148.	0.6	11
900	Immunotherapy and immunoescape in colorectal cancer. World Journal of Gastroenterology, 2007, 13, 5822.	1.4	36
901	Metronomic chemotherapy in nonâ€'small cell lung cancer (Review). Oncology Letters, 2020, 20, 1-1.	0.8	11
902	L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. Journal of Thoracic Disease, 2014, 6, 1513-20.	0.6	17
903	Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Translational Lung Cancer Research, 2014, 3, 34-45.	1.3	22
904	Chemically enhanced radiotherapy: visions for the future. Annals of Translational Medicine, 2016, 4, 52.	0.7	8
905	Enhancing the anticancer effects of 5-fluorouracil: Current challenges and future perspectives. Biomedical Journal, 2015, 38, 111.	1.4	42
906	Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center. Indian Journal of Cancer, 2018, 55, 94.	0.2	10
907	Immunobiology of Monocytes/Macrophages in Hepatocellular Carcinoma. , 0, , .		2
908	Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics, 2012, 67, 483-488.	0.6	47
909	The Concept of Hormesis in Cancer Therapy â€“ Is Less More?. Cureus, 2015, 7, e261.	0.2	12
910	Cancer Microbiome and Immunotherapy: Understanding the Complex Responses Between Microbes, Immunity, and Cancer. , 2021, , 83-99.		0
911	Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery. International Journal of Molecular Sciences, 2021, 22, 11378.	1.8	13
912	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight, 2021, 6, .	2.3	2
913	The perplexing role of immuno-oncology drugs in osteosarcoma. Journal of Bone Oncology, 2021, 31, 100400.	1.0	4
914	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. European Journal of Cancer, 2021, 158, 47-62.	1.3	32

#	Article	IF	Citations
915	Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease. , 2008, , 63-80.		1
916	Effects of Tumor Microenvironment on Immunity and Consequent Clinical Considerations. , 2009, , 157-179.		0
917	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2010, , 1269-1318.		0
918	CTLA-4 Blockade for Prostate Cancer Treatment. , 2010, , 343-348.		0
919	Metronomic Therapy for HIV-Associated Malignancies. , 2010, , 199-210.		0
920	Targeting regulatory T cells and other strategies to enable cancer vaccines. , 2011, , 182-201.		0
921	Entering a New Era â€“ Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T. , 0, , .		0
922	Adoptive Immunotherapy of Melanoma. , 2012, , 439-465.		0
923	Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. Journal of Clinical & Cellular Immunology, 2012, 01, 004.	1.5	2
924	Immunotherapy of Hepatocellular Carcinoma. , 2012, , 299-337.		0
926	Recent Advances in Cancer Immunotherapy. Practica Otologica, 2012, 105, 87-94.	0.0	0
927	Immuno-Oncology and Immunotherapy. , 0, , .		0
928	The Role of Immunotherapy in the Treatment of Mesothelioma. , 0, , .		0
929	Miscellaneous Approaches and Considerations: TLR Agonists and Other Inflammatory Agents, Anti-Chemokine Agents, Infectious Agents, Tumor Stroma Targeting, Age and Sex Effects, and Miscellaneous Small Molecules. , 2013, , 399-424.		0
930	Activation of Immune-Mediated Tumor Cell Death by Chemotherapy. , 2013, , 373-399.		0
931	Therapeutic Targeting Regulatory T Cells in Tumor. , 2013, , 585-602.		0
932	Development of Antitumor Cellular Immunity. , 2013, , 107-133.		0
933	Cancer Vaccines and the Potential Benefit of Combination with Standard Cancer Therapies. , 2013, , 347-359.		0

#	Article	IF	Citations
934	The Immune System in Head and Neck Squamous Cell Carcinoma: Interactions and Therapeutic Opportunities. , 2014, , 275-321.		0
935	What Is the Future of Immunotherapy in Ovarian Cancer?. , 2014, , 323-337.		0
936	Regulatory T Cells and Cancer. , 2014, , 1-36.		0
938	Metronomic Chemotherapy in Hematological Malignancies. , 2014, , 173-188.		0
939	Clinical Trials of Low-Dose Metronomic Chemotherapy in Castration-Resistant Prostate Cancer. , 2014, , 119-134.		1
940	Metronomic Chemotherapy in Non-Small-Cell Lung Cancer. , 2014, , 217-226.		0
942	The Anti-Proliferative Effect of 5-Fluorouracil on Tumor Is Highly Associated with the Renewal of Peripheral White Blood Cells. Journal of Cancer Therapy, 2015, 06, 594-600.	0.1	0
943	Novel Approach to Chemotherapy and Administration Selection with Metronomic/Fractionated Dosing. Journal of Cancer Therapy, 2015, 06, 455-465.	0.1	0
944	Clinical Trials of PARP Inhibitors with Chemotherapy. Cancer Drug Discovery and Development, 2015, , 511-531.	0.2	0
945	Immunogenic Chemotherapy Using Cyclophosphamide and Gemcitabine. Immunotherapy (Los Angeles,) Tj ETQq1 1 0.784314 rgBT /Ov	0.1	0
946	Antitumor Effects of IL-12 in Preclinical Studies. SpringerBriefs in Immunology, 2016, , 21-41.	0.1	0
947	Cancer Vaccines. , 2016, , 295-333.		0
948	MODERN POSSIBILITIES OF APPLICATION OF PREPARATION NAVELBINEÂ® IN THE TREATMENT OF METASTATIC BREAST CANCER. IssledovaniÃ¢ I Praktika V Medicine, 2016, 3, 71-77.	0.1	0
949	The Future in Ovarian Cancer: Advances in Immunotherapies. , 2017, , 143-168.		0
950	Chest Wall Disease: The Clinical Continuum Between Inflammatory and Lymphangitic Breast Cancer. , 2017, , 719-727.		0
951	Metronomic chemotherapy with vinorelbine as the optimal treatment option in real clinical practice. Onkologiya Zhurnal Imeni P A Gertsena, 2017, 6, 64.	0.0	1
952	Re-Thinking the Interplay between Tumorigenesis and Immunity. Journal of Cell Signaling, 2017, 01, .	0.3	0
953	New Progress in Breast Cancer Immunotherapy. Advances in Clinical Medicine, 2018, 08, 47-52.	0.0	0

#	Article	IF	Citations
954	Regulatory T Cells in Colorectal Cancer. Immunoregulation, 0, , 5-10.	0.1	1
955	Immunotherapy in Oncology. , 2020, , 3-6.		0
956	Immunotherapy for cancer of the oral cavity and oropharynx. Bukovinian Medical Herald, 2020, 24, 234-241.	0.1	0
957	Current regimens for use of vinorelbine in metastatic breast cancer: role and place of oral dosage form, metronome therapy, combinations with anti-HER 2 drugs. Medical Alphabet, 2020, , 6-11.	0.0	0
958	Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment. Cancers, 2021, 13, 5414.	1.7	8
959	Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds. Cancer Letters, 2022, 524, 144-150.	3.2	7
960	Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity. Drug Delivery, 2021, 28, 2313-2328.	2.5	5
962	Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers. , 2021, , 169-182.		0
965	Morphoproteomics provides support for TGF-Î² pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis. International Journal of Clinical and Experimental Pathology, 2012, 5, 503-11.	0.5	28
966	Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?. American Journal of Blood Research, 2013, 3, 52-7.	0.6	17
968	Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up. Translational Andrology and Urology, 2012, 1, 229-233.	0.6	0
973	Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opinion on Investigational Drugs, 2022, 31, 557-565.	1.9	52
974	Research Progress on the Role of Regulatory T Cell in Tumor Microenvironment in the Treatment of Breast Cancer. Frontiers in Oncology, 2021, 11, 766248.	1.3	7
975	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers, 2021, 13, 5819.	1.7	4
976	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2021, 11, 804714.	1.3	9
977	Metronomic chemotherapy and antiangiogenic drugs: Preclinical and clinical data. , 2022, , 127-146.		0
978	So Pathogenic or So What?â€"A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research. Viruses, 2022, 14, 135.	1.5	5
979	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 832942.	2.2	18

#	Article	IF	Citations
980	The immunopathogenesis of idiopathic nephrotic syndrome: a narrative review of the literature. European Journal of Pediatrics, 2022, 181, 1395-1404.	1.3	4
981	The Spectrum of Histomorphological Changes and Pathological Tumor Response following Preoperative Oral Metronomic Chemotherapy in Oral Squamous Cell Carcinoma. South Asian Journal of Cancer, 0, , .	0.2	0
982	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
983	Combinatorial immunotherapy strategies for cancer vaccines. , 2022, , 137-154.		0
984	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	3.8	13
985	Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy. Frontiers in Immunology, 2022, 13, 790113.	2.2	23
986	Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies. Breast Cancer Research and Treatment, 2022, 193, 21-35.	1.1	4
987	Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma. Oncotarget, 2022, 13, 490-504.	0.8	2
988	Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice. Immunobiology, 2022, 227, 152212.	0.8	2
989	Targeting T regulatory cells: Their role in colorectal carcinoma progression and current clinical trials. Pharmacological Research, 2022, 178, 106197.	3.1	2
990	Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. International Immunopharmacology, 2022, 106, 108628.	1.7	1
991	Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-15.	0.5	7
992	Chemotherapy Effects on Immune System. , 2022, , 287-302.		3
1000	The interplay of immunotherapy, chemotherapy, and targeted therapy in tripple negative breast cancer (TNBC). , 2022, , 149-176.		5
1001	Clinical advances in oncolytic virotherapy for pediatric brain tumors. , 2022, 239, 108193.		21
1002	Identification of EPZ004777 and FG2216 as inhibitors of TGF-Î²1 induced Treg cells by screening a library of epigenetic compounds. Life Sciences, 2022, 301, 120643.	2.0	0
1003	Long-term survival of a feline with non-T/B large granular lymphocyte lymphoma treated with chemotherapy and activated lymphocyte therapy. Open Veterinary Journal, 2022, 12, 312.	0.3	0
1004	Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2022, 12, .	1.3	0

#	Article	IF	Citations
1005	Metronomic Chemotherapy in Prostate Cancer. Journal of Clinical Medicine, 2022, 11, 2853.	1.0	6
1006	Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature. Journal of Clinical Medicine, 2022, 11, 2849.	1.0	4
1007	Neoadjuvant immunotherapy in gastrointestinal cancers â€“ The new standard of care?. Seminars in Cancer Biology, 2022, 86, 834-850.	4.3	12
1008	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210998.	0.6	10
1009	The Nitrogen Mustards. Pharmacological Reviews, 2022, 74, 552-599.	7.1	13
1010	Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-Î² signaling in regulatory TÂcells. Cell Reports, 2022, 39, 110986.	2.9	82
1011	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540.	21.5	134
1012	Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine. Biomedicine and Pharmacotherapy, 2022, 152, 113250.	2.5	28
1013	Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer. Frontiers in Immunology, 0, 13, .	2.2	9
1014	Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Frontiers in Immunology, 0, 13, .	2.2	23
1015	Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. Expert Opinion on Investigational Drugs, 2022, 31, 855-874.	1.9	2
1016	Recent Advances in Immunotherapy for the Treatment of Malignant Melanoma. Current Pharmaceutical Design, 2022, 28, 2363-2374.	0.9	3
1017	How Chemotherapy Affects the Tumor Immune Microenvironment: A Narrative Review. Biomedicines, 2022, 10, 1822.	1.4	11
1018	Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. Cancers, 2022, 14, 3808.	1.7	2
1019	Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer. Oncology Research and Treatment, 2022, 45, 681-692.	0.8	7
1020	Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	6
1021	Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study. BMC Cancer, 2022, 22, .	1.1	5
1022	Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. Heliyon, 2022, 8, e10450.	1.4	5

#	Article	IF	Citations
1023	Maintenance tegafur-plus-uracil after adjuvant concurrent chemoradiotherapy may improve outcome for resected oral cavity squamous cell carcinoma with extranodal extension. Frontiers in Oncology, 0, 12, .	1.3	0
1024	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. OncoImmunology, 2022, 11, .	2.1	28
1025	Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Antiâ€“PD-1â€“Resistant Advanced Melanoma. Clinical Cancer Research, 2023, 29, 100-109.	3.2	19
1026	Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. Expert Review of Clinical Pharmacology, 2022, 15, 1399-1413.	1.3	3
1027	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
1028	Immunological Effects of Conventional Anticancer Drugs. , 2022, , 1-13.		0
1031	Immunosuppressive Therapy in Giant Cell Arteritis: Do Steroids Still Reign Supreme?. , 2022, 16, 85.		0
1032	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. OncoImmunology, 2023, 12, .	2.1	7
1033	Refurbishment of NK cell effector functions through their receptors by depleting the activity of nTreg cells in Daltonâ€™s Lymphoma-induced tumor microenvironment: an in vitro and in vivo study. Cancer Immunology, Immunotherapy, 2023, 72, 1429-1444.	2.0	1
1034	Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nature Medicine, 2022, 28, 2573-2583.	15.2	25
1035	Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578.	1.7	1
1036	The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment. Frontiers in Immunology, 0, 13, .	2.2	1
1037	CD4+ TÂcells drive an inflammatory, TNF-Î±/IFN-rich tumor microenvironment responsive to chemotherapy. Cell Reports, 2022, 41, 111874.	2.9	4
1038	Immunogenic Cell Death in Cancer. , 2023, , .		0
1039	Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system. , 2023, , 301-320.		1
1040	Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention. Biomolecules, 2023, 13, 653.	1.8	0
1041	Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?. Cancer Letters, 2023, 562, 216168.	3.2	7
1042	Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review. Frontiers in Oncology, 0, 13, .	1.3	0

#	Article	IF	Citations
1043	Comparative study on the impacts of visnagin and its methoxy derivative khellin on human lymphocyte proliferation and Th1/Th2 balance. Pharmacological Reports, 2023, 75, 411-422.	1.5	2
1044	Tailoring therapies to counter the divergent immune landscapes of breast cancer. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	3
1045	Combination therapy of oral cyclophosphamide and bevacizumab for patients with recurrent ovarian and peritoneal cancer. Medicine (United States), 2023, 102, e32880.	0.4	2
1046	Boosting In-Vivo Anti-Tumor Immunity with an Oral Microparticulate Breast Cancer Vaccine and Low-Dose Cyclophosphamide. Vaccines, 2023, 11, 543.	2.1	1
1047	Combining chemotherapy with CAR-T cell therapy in treating solid tumors. Frontiers in Immunology, 0, 14, .	2.2	10
1048	Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype. Biomedicines, 2023, 11, 874.	1.4	1
1049	First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). , 2023, 11, e005301.		5
1050	Toxoplasma gondii-derived antigen modifies tumor microenvironment of Ehrlich solid carcinoma murine model and enhances immunotherapeutic activity of cyclophosphamide. , 2023, 40, .		1
1051	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. Journal of Hematology and Oncology, 2023, 16, .	6.9	14
1052	Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Frontiers in Pharmacology, 0, 14, .	1.6	13
1064	Oral Metronomic Chemotherapy in Advanced and Metastatic Oral Squamous Cell Carcinoma: A Need of the Hour. Journal of Maxillofacial and Oral Surgery, 0, , .	0.6	2
1070	Metronomic Chemotherapy. , 2023, , 41-56.		0
1073	Heterogeneity and treatment landscape of ovarian carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 820-842.	12.5	3